# Wortham Laboratories, Inc.

# Premarket Notification 510 (k) Summary

# Stasis 1 Coagulation Control

The assigned 510K number is: K060968

# Applicant:

Wortham Laboratories, Inc. 6340 Bonny Oaks Dr Chattanooga, TN 37416 Tel: (423) 296-0090 Fax: (423) 296-0188

# Contact:

Leon Wortham

# Date:

April 6, 2007

# Device Name:

Wortham Laboratorics Stasis 1 Coagulation Control (Normal)

Common Name:

Normal Coagulation Control

Classification Name:

Plasma, Coagulation Control, a class II device as per 21 CFR section 864.5425 (Product Code GGC). This device is intended for clinical use in conjunction with an analyzer to measure clot formation.

# Predicate:

Pacific Hemostasis Coagulation Control Level I (K984129)

# Description

Wortham Laboratories Stasis  Coagulation Control (Normal) is a liquid stable citrated plasma obtained from ySr buav be he pc ulu preparation f the control has been tested by an FDA approved method and found t be non-reactive or HBsA and negative for antibodies to H1V and HCV.

# Intended Use

Wortham Laboratoris Stasis Coagulation Control (Normal) is intende o us s a qualiy control toonir he prc  rothobin ime  Activate rtal Trooplastn ime Tn Fren assy It will yicld PT, APTT, and Fibrinogen values in the normal range.

# Labeling

This device is labcled in accordance with 21 CFR 801.

# Substantial Equivalence

<table><tr><td rowspan=1 colspan=1>CharacteristicsIntended Use</td><td rowspan=1 colspan=4>New DeviceRoutine coagulation for PT, PTT, fibrinogenassays in the normal range</td><td rowspan=1 colspan=3>PredicateRoutine coagulation for PT, PTT, fibrinogenassays in the normal range</td></tr><tr><td rowspan=1 colspan=1></td><td></td><td></td><td></td><td></td><td rowspan=1 colspan=3></td></tr><tr><td rowspan=1 colspan=1>ControlComposition</td><td rowspan=1 colspan=4>Liquid Human citrated plasma</td><td rowspan=1 colspan=3>Lypholyzed human citrated plasma</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=4></td><td rowspan=1 colspan=3></td></tr><tr><td rowspan=1 colspan=1>Stability</td><td rowspan=1 colspan=4>12 months @ ≤ -2°C30 days @ 2-4° C</td><td rowspan=1 colspan=3>35 months @ 2-8° C, lypholyzed8 hours @ 2-8° C, rehydrated</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=4></td><td rowspan=1 colspan=3></td></tr><tr><td rowspan=1 colspan=1>ReferenceValues</td><td rowspan=1 colspan=3>CV%</td><td rowspan=1 colspan=1>PT</td><td rowspan=1 colspan=2>CV%</td><td rowspan=1 colspan=1>PT</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>within-run (ISI=1.54)</td><td rowspan=1 colspan=1>0.75%</td><td rowspan=1 colspan=2>within-run (ISI=1.54)</td><td rowspan=1 colspan=1>0.90%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>within-run (ISI=1.20)</td><td rowspan=1 colspan=1>0.88%</td><td rowspan=1 colspan=2>within-run (ISI=1.20)</td><td rowspan=1 colspan=1>1.40%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>run-run (ISI=1.54)</td><td rowspan=1 colspan=1>0.67%</td><td rowspan=1 colspan=2>run-run (ISI=1.54)</td><td rowspan=1 colspan=1>0.85%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>run-run (ISI=1.20)</td><td rowspan=1 colspan=1>0.89%</td><td rowspan=1 colspan=2>run-run (ISI=1.20)</td><td rowspan=1 colspan=1>1.38%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>CV%</td><td rowspan=1 colspan=1>APTT</td><td rowspan=1 colspan=2>CV%</td><td rowspan=1 colspan=1>APTT</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>within-run (Kaolin)</td><td rowspan=1 colspan=1>0.63%</td><td rowspan=1 colspan=2>within-run (Kaolin)</td><td rowspan=1 colspan=1>1.54%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>within-run (Ellagic-Acid)</td><td rowspan=1 colspan=1>0.62%</td><td rowspan=1 colspan=2>within-run (Ellagic-Acid)</td><td rowspan=1 colspan=1>0.85%</td></tr><tr><td rowspan=1 colspan=1>cYanmaGelow</td><td rowspan=1 colspan=3>run-run (Kaolin)</td><td rowspan=1 colspan=1>0.61%</td><td rowspan=1 colspan=2>run-run (Kaolin)</td><td rowspan=1 colspan=1>1.20%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>run-run (Ellagic Acid)</td><td rowspan=1 colspan=1>0.60%</td><td rowspan=1 colspan=2>run-run (Ellagic Acid)</td><td rowspan=1 colspan=1>0.85%</td></tr><tr><td rowspan=1 colspan=1>cYanmaentaYellowb</td><td rowspan=1 colspan=3></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>CV%</td><td rowspan=1 colspan=1>Fibrinogen</td><td rowspan=1 colspan=2>CV%</td><td rowspan=1 colspan=1>Fibrinogen</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>within-run</td><td rowspan=1 colspan=1>0.56%</td><td rowspan=1 colspan=2>within-run</td><td rowspan=1 colspan=1>0.59%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>run-run</td><td rowspan=1 colspan=1>0.57%</td><td rowspan=1 colspan=2>run-run</td><td rowspan=1 colspan=1>0.60%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=4></td><td rowspan=1 colspan=3></td></tr><tr><td rowspan=1 colspan=1>Expected Range</td><td rowspan=1 colspan=1>Mechanical</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=2>±2SD</td><td rowspan=1 colspan=1>Mechanical</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>± 2SD</td></tr><tr><td rowspan=1 colspan=1>cYanmaGtaYow</td><td rowspan=1 colspan=1>PT</td><td rowspan=1 colspan=1>11.67</td><td rowspan=1 colspan=2>11.5-11.8 sec</td><td rowspan=1 colspan=1>PT</td><td rowspan=1 colspan=1>11.66</td><td rowspan=1 colspan=1>11.4-11.9 sec</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>APTT:</td><td rowspan=1 colspan=1>29.51</td><td rowspan=1 colspan=2>29.3-29.7 sec</td><td rowspan=1 colspan=1>APTT:</td><td rowspan=1 colspan=1>28.38</td><td rowspan=1 colspan=1>28.0-28.8 sec</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Fibrinogen:</td><td rowspan=1 colspan=1>306.3</td><td rowspan=1 colspan=2>301-313 g/dl</td><td rowspan=1 colspan=1>Fibrinogen:</td><td rowspan=1 colspan=1>306.3</td><td rowspan=1 colspan=1>297-315 g/dl</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=4></td><td rowspan=1 colspan=3></td></tr><tr><td rowspan=1 colspan=1>Storage</td><td rowspan=1 colspan=4>$≤-2o$</td><td rowspan=1 colspan=3>2-8°C</td></tr><tr><td rowspan=1 colspan=1></td><td></td><td></td><td></td><td></td><td rowspan=1 colspan=3></td></tr><tr><td rowspan=1 colspan=1>Assay Factors</td><td rowspan=1 colspan=4>PT, APTT, Fibrinogen</td><td rowspan=1 colspan=3>PT, APTT, Fibrinogen</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=4></td><td rowspan=1 colspan=3></td></tr></table>

# Conclusions

# Stasis 1

Wortham Laboratories Stasis and Paciic Hemostasis Coagulation Control Level I have the same intendeduse, as alcntrolsr he qaiaiveeementhe rombne  Activat artl rbl Time (APTT) and fibrinogen levels.Both are preparations of citrate plasma obtained from normal donors with added stabilizers and buffers.

Mechanical assays of Stasis  to the predicatenormal plasma control with two different sensitive troboplastn rns, with n IS  1.0 an 1.58, yelde a withi-un standardevitio 0809 and 0.0922 or St resetively, compared to a 0.1714 and a 0.1050 S for the predicate control from the same reagents.A rprecision of Stasis 1 produced a 0.1026 and 0.0784 SD with the two thromboplastin reagents, compared to 0.1733 and 0.0987 SD of Pacific Hemostasis Control.

Mechanical measurements of theAPTT in both Stasis and Pacific Hemostasis Levcl 1Control with two different acivator reagents, Kaolin and ellagic acid, produced a within-run 0.0863 and a 0.1792 standard deviation, retively, while the preicate control yiclded a 0.1989 and a 0.2455 D.A run-run precision of the Sas Control measured at 0.1705 and 0.1749 SD to the two APTT activators, contrasted to Paciic Hemostasis Level I Controls 0.3339 and 0.2453 SD.

The prsing    evlsn boh stu aphs n heeestnt pu  wi 0.050 and a 0.0858 un-un standarddeviatin or Stas, whic a within-un 0.089 SDand run-un 0.0900 SD was observed in the Pacific Hemostasis Level 1 Control.

Reproducibility of the two controls yielded a $0 . 8 6 \%$ within-run coefficient of variation and a run-run $0 . 8 9 \%$ CV for Stasis 1, comparcd respectivcly to the predicate control of $1 . 3 6 \%$ CV and $1 . 3 8 \%$ CV.

The pe ehee  we s eihabtnologi support the substantial equivalence claim for Wortham Laboratories Stasis 1 Coagulation Control to Pacific Hemostas Coagulaton ControlLevel Basen he ata provie ur conclusion that heseo pruct are substantially equivalent.

# Wortham Laboratories, Inc.

# Premarket Notification 510 (k) Summary

# Stasis 2 Coagulation Control

The assigned 510K number is: K060968

# Applicant:

Wortham Laboratories, Inc. 6340 Bonny Oaks Dr Chattanooga, TN 37416 Tel: (423) 296-0090 Fax: (423) 296-0188

# Contact:

Lcon Wortham

# Date:

April 6, 2007

# Device Name:

Wortham Laboratories Stasis 2 Coagulation Control (Abnormal)

Common Name:

Abnormal Coagulation Control

Classification Name:

Plasma, Coagulation Control, a class II device as per 21 CFR section 864.5425 (Product Code GGC). This device is intended for clinical use in conjunction with an analyzer to measure clot formation.

# Predicate:

Pacific Hemostasis Coagulation Control Level II (K984130)

# Description

Wortham Laboratories Stasis 2 Coagulation Control (Abnormal) is a liquid stable citrated plasma obtaind from ySzrnbuav bee pcalu peaat the control has been teste by an FDA apovemethod anfound  be on-eactiv r HBsA an negative for antibodies to HIV and HCV.

# Intended Use

Wortham Laboratoris Stasis  Coagulation Control Abnormal)iintended oruse s a quality control oo t peorm rothr Time T), Activat PartalThroastn ime ATT It wil yield T, APTT values in the moderate abnormal range.

# Labcling

This device is labeled in accordance with 21 CFR 801.

# Substantial Equivalence

<table><tr><td rowspan=1 colspan=1>CharacteristicsIntended Use</td><td rowspan=1 colspan=4>New DeviceRoutine coagulation for PT, PTT, assays in themoderately abnormal range</td><td rowspan=1 colspan=3>PredicateRoutine coagulation for PT, PTT, assays inthe moderately abnormal range</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=4>Y</td><td rowspan=1 colspan=3>EY</td></tr><tr><td rowspan=1 colspan=1>ControlComposition</td><td rowspan=1 colspan=4>Liquid Human citrated plasma</td><td rowspan=1 colspan=3>Lypholyzed human citrated plasma</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=4>Y</td><td rowspan=1 colspan=3>EY</td></tr><tr><td rowspan=1 colspan=1>Stability</td><td rowspan=1 colspan=4>12 months @ ≤ -2°C30 days @ 2-4° C</td><td rowspan=1 colspan=3>34 months @ 2-8° C, lypholyzed8 hours @ 2-8° C, rchydrated</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=4>Y</td><td rowspan=1 colspan=3></td></tr><tr><td rowspan=1 colspan=1>ReferenceValues</td><td rowspan=1 colspan=3>CV%</td><td rowspan=1 colspan=1>PT</td><td rowspan=1 colspan=2>CV%</td><td rowspan=1 colspan=1>PT</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>within-run (IS1=1.54)</td><td rowspan=1 colspan=1>1.01%</td><td rowspan=1 colspan=2>within-run (ISI=1.54)</td><td rowspan=1 colspan=1>1.41%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>within-run (ISI=1.20)</td><td rowspan=1 colspan=1>1.10%</td><td rowspan=1 colspan=2>within-run (ISI-1.20)</td><td rowspan=1 colspan=1>1.28%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>run-run (IS1=1.54)</td><td rowspan=1 colspan=1>0.98%</td><td rowspan=1 colspan=2>run-run (ISI=1.54)</td><td rowspan=1 colspan=1>1.30%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>run-run (ISI=1.20)</td><td rowspan=1 colspan=1>1.01%</td><td rowspan=1 colspan=2>run-run (ISI=1.20)</td><td rowspan=1 colspan=1>1.19%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>CV%</td><td rowspan=1 colspan=1>APTT</td><td rowspan=1 colspan=2>CV%</td><td rowspan=1 colspan=1>APTT</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>within-run (Kaolin)</td><td rowspan=1 colspan=1>0.76%</td><td rowspan=1 colspan=2>within-run (Kaolin)</td><td rowspan=1 colspan=1>1.00%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>within-run (Ellagic-Acid)</td><td rowspan=1 colspan=1>0.50%</td><td rowspan=1 colspan=2>within-run (Ellagic-Acid)</td><td rowspan=1 colspan=1>0.91%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>run-run (Kaolin)</td><td rowspan=1 colspan=1>0.76%</td><td rowspan=1 colspan=2>run-run (Kaolin)</td><td rowspan=1 colspan=1>1.06%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>run-run (Ellagic Acid)</td><td rowspan=1 colspan=1>0.48%</td><td rowspan=1 colspan=2>run-run (Ellagic Acid)</td><td rowspan=1 colspan=1>0.90%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=4>Y</td><td rowspan=1 colspan=3></td></tr><tr><td rowspan=1 colspan=1>Expected Range</td><td rowspan=1 colspan=1>Mechanical</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=2>±2SD</td><td rowspan=1 colspan=1>Mechanical</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>± 2SD</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>PT</td><td rowspan=1 colspan=1>20.14</td><td rowspan=1 colspan=2>19.9-20.3 sec</td><td rowspan=1 colspan=1>PT</td><td rowspan=1 colspan=1>20.25</td><td rowspan=1 colspan=1>19.7-20.8 sec</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>APTT:</td><td rowspan=1 colspan=1>55.75</td><td rowspan=1 colspan=2>54.9-56.6 sec</td><td rowspan=1 colspan=1>APTT:</td><td rowspan=1 colspan=1>55.01</td><td rowspan=1 colspan=1>53.9-56.2 sec</td></tr><tr><td rowspan=1 colspan=1></td><td></td><td></td><td></td><td></td><td rowspan=1 colspan=3>EY</td></tr><tr><td rowspan=1 colspan=1>Storage</td><td rowspan=1 colspan=4>≤-2°C</td><td rowspan=1 colspan=3>2-8oC</td></tr><tr><td rowspan=1 colspan=1></td><td></td><td></td><td></td><td></td><td rowspan=1 colspan=3>EY</td></tr><tr><td rowspan=1 colspan=1>Assay Factors</td><td rowspan=1 colspan=4>PT, APTT</td><td rowspan=1 colspan=3>PT, APTT</td></tr><tr><td rowspan=1 colspan=1></td><td></td><td></td><td></td><td></td><td rowspan=1 colspan=3></td></tr></table>

# Conclusions

# Stasis 2

Worthm Laboratoris Stasis  nd aciicHemostasis Coagulation Control Level I have  same intendedus, as a cnols r he ivemen he roon  Actva ar Tim (APTT).Both are preparations of cirate plasma obtaine from normal donors with ade stabilizers and buffers.

Mechanical assays Stas  t the preicatemoderately anormal plasa control with tw different sesive thromboplastin reagents, 1.20 ISI and 1.58 IS1, yielded a standard deviation of 0.5992 and 0.2023 for Stasis 2 retively,cpared to a 0.438 SD and a 0.2856 SD or he predicatecontol from the ae reagents.A precision of Stasis 2 produced a 0.3664 and 0.1984 SD with the two thromboplastin reagents, compared to 0.4296 and 0.2644 SD of Pacific Hemostasis Control.

Mechanical measurements f the APTT in both Stasis  and Paciic Hemostasis Level I Control with two diffent avat Ko n ella pu 0.1 nd  0.3rdvi, iv the predicate control yiclded a 0.5721 and a 0.4045 SD.A run-run precision of the Stasis 2 Control measured at 0.4136 and 0.2233 SD to the two APTT activators, contrasted to Pacific Hemostasis Level I Controls 0.5628 and 0.4043 SD.

Reproducibility of the two controls yielded a $1 , 1 0 \%$ within-run cocfficient of variation and a run-run $1 . 0 1 \%$ CV for Stasis 2, compared respectively to the predicate control of $1 . 2 8 \%$ CV and $1 . 1 9 \%$ CV.

The peat erea w shenigshabtenu n oogil support the substantial equivalence claim for Wortham Laboratories Stasis 2 Coagulation Control to Pacific Hmsas glation ConolLevl Basn he ta provide sur oncuson that theseto are substantially equivalent.

# Wortham Laboratories, Inc.

# Premarket Notification 510 (k) Summary

Stasis 3 Coagulation Control

The assigned 510K number is: K060968

# Applicant:

Wortham Laboratories, Inc. 6340 Bonny Oaks Dr Chattanooga, TN 37416 Tel: (423) 296-0090 Fax: (423) 296-0188

# Contact:

Leon Wortham

# Date:

April 6, 2007

# Device Name:

Wortham Laboratorics Stasis 3 Coagulation Control (Abnormal)

# Common Name:

Abnormal Coagulation Control

Classification Name:

Plasma, Coagulation Control, a class II device as pcr 21 CFR section 864.5425 (Product Code GGC). This device is intended for clinical use in conjunction with an analyzer to measure clot formation.

# Predicate:

Pacific Hemostasis Coagulation Control Level III (K984131)

# Description

Wortham Laboratories Stasis 3 Coagulation Control (Abnormal) is a liquid stable citrated plasma obtained from ySzrbuhav ee  pcu prepaatin the control has been tested by an FDA aprove metod anfound  be non-reactive r HBsA an negative for antibodies to HIV and HCV.

# Intended Use

Wortham Laboratoris Stasis 3 Coagulation Control Anormal) isntended or use as a quality control t te pcPro Time T Activate artalThroolastme TIt wilyicld , a APTT values in the strongly abnormal range.

# Labeling

This device is labeled in accordance with 21 CFR 801.

# Substantial Equivalence

<table><tr><td rowspan=1 colspan=1>CharacteristicsIntended Use</td><td rowspan=1 colspan=4>New DeviceRoutine coagulation for PT, PTT, assays in thehigh abnormal range</td><td rowspan=1 colspan=3>PredicateRoutine coagulation for PT, PTT, assays inthe high abnormal range</td></tr><tr><td rowspan=1 colspan=1></td><td></td><td></td><td></td><td></td><td rowspan=1 colspan=3>EY</td></tr><tr><td rowspan=1 colspan=1>ControlComposition</td><td rowspan=1 colspan=4>Liquid Human citrated plasma</td><td rowspan=1 colspan=3>Lypholyzed human citrated plasma</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=4>EY</td><td rowspan=1 colspan=3>EY</td></tr><tr><td rowspan=1 colspan=1>Stability</td><td rowspan=1 colspan=4>12 months @ ≤ -2° C30 days @ 2-4° C</td><td rowspan=1 colspan=3>35 months @ 2-8° C, lypholyzed8 hours @ 2-8° C, rehydrated</td></tr><tr><td rowspan=1 colspan=1></td><td></td><td></td><td></td><td></td><td rowspan=1 colspan=3></td></tr><tr><td rowspan=1 colspan=1>ReferenceValucs</td><td rowspan=1 colspan=3>CV%</td><td rowspan=1 colspan=1>PT</td><td rowspan=1 colspan=2>CV%</td><td rowspan=1 colspan=1>P$</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>within-run (ISI=1.54)</td><td rowspan=1 colspan=1>1.45%</td><td rowspan=1 colspan=2>within-run (ISI=1.54)</td><td rowspan=1 colspan=1>1.68%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>within-run (ISI=1.20)</td><td rowspan=1 colspan=1>1.36%</td><td rowspan=1 colspan=2>within-run (ISI=1.20)</td><td rowspan=1 colspan=1>1.52%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>run-run (ISI=1.54)</td><td rowspan=1 colspan=1>1.46%</td><td rowspan=1 colspan=2>run-run(ISI=1.54)</td><td rowspan=1 colspan=1>1.70%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>run-run (ISI=1.20)</td><td rowspan=1 colspan=1>1.44%</td><td rowspan=1 colspan=2>run-run (ISI=1.20)</td><td rowspan=1 colspan=1>1.34%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>CV%</td><td rowspan=1 colspan=1>APTT</td><td rowspan=1 colspan=2>CV%</td><td rowspan=1 colspan=1>APTT</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>within-run (Kaolin)</td><td rowspan=1 colspan=1>0.80%</td><td rowspan=1 colspan=2>within-run (Kaolin)</td><td rowspan=1 colspan=1>1.12%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>within-run (Ellagic-Acid)</td><td rowspan=1 colspan=1>0.76%</td><td rowspan=1 colspan=2>within-run (Ellagic-Acid)</td><td rowspan=1 colspan=1>1.12%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>run-run (Kaolin)</td><td rowspan=1 colspan=1>0.75%</td><td rowspan=1 colspan=2>run-run (Kaolin)</td><td rowspan=1 colspan=1>1.15%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>run-run (Ellagic Acid)</td><td rowspan=1 colspan=1>0.75%</td><td rowspan=1 colspan=2>run-run (Ellagic Acid)</td><td rowspan=1 colspan=1>1.11%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=4></td><td rowspan=1 colspan=3></td></tr><tr><td rowspan=1 colspan=1>Expected Range</td><td rowspan=1 colspan=1>Mechanical</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=2>± 2SD</td><td rowspan=1 colspan=1>Mechanical</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>± 2SD</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>PT</td><td rowspan=1 colspan=1>32.50</td><td rowspan=1 colspan=2>32.0-33.0 sec</td><td rowspan=1 colspan=1>PT</td><td rowspan=1 colspan=1>32.49</td><td rowspan=1 colspan=1>31.4-33.6 sec</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>APTT:</td><td rowspan=1 colspan=1>70.49</td><td rowspan=1 colspan=2>69.4-71.5 sec</td><td rowspan=1 colspan=1>APTT:</td><td rowspan=1 colspan=1>70.13</td><td rowspan=1 colspan=1>68.8-71.4 scc</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=4></td><td rowspan=1 colspan=3></td></tr><tr><td rowspan=1 colspan=1>Storage</td><td rowspan=1 colspan=4>≤-2°C</td><td rowspan=1 colspan=3>2-8oC</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=4></td><td rowspan=1 colspan=3></td></tr><tr><td rowspan=1 colspan=1>Assay Factors</td><td rowspan=1 colspan=4>PT, APTT</td><td rowspan=1 colspan=3>PT, APTT</td></tr><tr><td rowspan=1 colspan=1></td><td></td><td></td><td></td><td></td><td rowspan=1 colspan=3></td></tr></table>

# Conclusions

# Stasis 3

Wortham Laboratories Stasis 3 and Pacific Hemostasis Coagulation Control Level hav the sam intendeduse, as nora cntrolrhe niaivement roombe  Activat artl Trobla Tim (APTT).Both are preparations citrate plasma btainefrom normal donors wit adde stabilizers and buffers.

Mechanical assays of Stasis 3 to the predicate moderately abnormal plasma control with two different sensiive thromboplastin reagents, 1.20 IS1 and 1.58 IS1, yiclded a standard deviation of 0.8385 and 0.4721 for Stasis 3 respetively, compared to a 0.9333 and a 0.5467 for the predicate control from the same reagents.A r-run precisionf Stass 3 produced a 0.841 and 0.4712 D with the two throboplastin reagents, compared to0.969 n 0.5512 SD of Pacific Hemostasis Control.

Mechanical measurments of the PTT in both Stasis 3 and PaciicHemostasis Level  ontrol with two diffnt avant Ko nella p 0.78 n  08nardvi, eiv the predicat control yielded a 0.645 and a 0.7160 D.A run-run precision f the Stasis 3 Control meas at 0.5273 and 0.4860 SD to the two APTT activators, contrasted to Pacific Hemostasis Level II Controls.0.8029 and 0.7133 SD.

Reproducibility of the two controls yielded a $1 . 3 5 \%$ within-run coefficient of variation and a run-run $1 . 3 6 \%$ CV for Stasis 3, compared respectively to the predicate control of $1 . 5 2 \%$ CV and $1 . 5 8 \%$ CV.

T p p   eatenog support the substantial equivalence claim for Wortham Laboratories Stasis 3 Coagulation Control to Pacific Hemostasi agulatio Contro Level Ias he at provieircuson hat heseo p are substantially equivalent.

# Wortham Laboratories, Inc.

# Premarket Notification 510 (k) Summary

# Serathan-B PT Reagent

The assigned 5 10K number is: K060968

# Applicant:

Wortham Laboratories, Inc. 6340 Bonny Oaks Dr Chattanooga, TN 37416 Tel: (423) 296-0090 Fax: (423) 296-0188

# Contact:

Leon Wortham

# Date:

April 6, 2007

# Device Name:

Wortham Laboratories Serathan-B PT Reagent.

# Common Name:

Prothrombin Time

Classification Name:

Prothrombin Time Test, is a class II device, as per 21 CFR 864.7750 (Product Code GJS). This device is intended for clinical use in conjunction with an analyzer to measure clot formation.

# Predicate:

Pacific Hemostasis Thromboplastin-D (K994100)

# Description

W R qabtlas stabilizer and buffr.Serathan-B is n in-vitro diagnostic reagent intended for use for the performance o Prothrombin Time (PT) testing and quantitative PT-based factor assays for Factors II, V. VII and X.

# Intended Use

Worm LabtorSrathan-B reagent is -disicraginte in cliical laboa t ivtulatlt extrinsic pathway. Serathan-B is a moderately sensitive thromboplastin reagent.

# Labeling

This device is labeled in accordance with 21 CFR 801.

# Substantial Equivalence

<table><tr><td rowspan=1 colspan=1>CharacteristicsIntended Use</td><td rowspan=1 colspan=5>New DevicePerformance of Prothrombin Time (PT) testingfor the detection of coagulation abnormalities inthe extrinsic pathway</td><td rowspan=1 colspan=5>PredicatePerformance of Prothrombin Time (PT)testing for the detection of coagulationabnormalities in the extrinsic pathway</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=5>EY</td><td rowspan=1 colspan=5></td></tr><tr><td rowspan=1 colspan=1>ReagentComposition</td><td rowspan=1 colspan=5>Liquid Rabbit Thromboplastin</td><td rowspan=1 colspan=5>Lypholyzed Rabbit Thromboplastin</td></tr><tr><td rowspan=1 colspan=1></td><td></td><td></td><td></td><td></td><td></td><td rowspan=1 colspan=5></td></tr><tr><td rowspan=1 colspan=1>Stability</td><td rowspan=1 colspan=5>12 months @ ≤ -2°C30 days @ 2-4° C</td><td rowspan=1 colspan=5>30 months @ 2-8° C, lypholyzed7 days @ 2-8° C, rehydrated</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3></td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=3>Y</td><td rowspan=1 colspan=2></td></tr><tr><td rowspan=1 colspan=1>ReferenceValues</td><td rowspan=1 colspan=3>within-run</td><td rowspan=1 colspan=2>CV%</td><td rowspan=1 colspan=3>within-run</td><td rowspan=1 colspan=2>CV%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Level I</td><td rowspan=1 colspan=2>0.80%</td><td rowspan=1 colspan=3>Level 1</td><td rowspan=1 colspan=2>0.90%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Level 2</td><td rowspan=1 colspan=2>1.27%</td><td rowspan=1 colspan=3>Level 2</td><td rowspan=1 colspan=2>1.41%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Level 3</td><td rowspan=1 colspan=2>1.42%</td><td rowspan=1 colspan=3>Level 3</td><td rowspan=1 colspan=2>1.68%</td></tr><tr><td rowspan=1 colspan=1>.</td><td rowspan=1 colspan=3></td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=3></td><td rowspan=1 colspan=2></td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>run-run</td><td rowspan=1 colspan=2>CV%</td><td rowspan=1 colspan=3>run-run</td><td rowspan=1 colspan=2>CV%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Level 1</td><td rowspan=1 colspan=2>1.75%</td><td rowspan=1 colspan=3>Level 1</td><td rowspan=1 colspan=2>0.85%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Level 2</td><td rowspan=1 colspan=2>1.22%</td><td rowspan=1 colspan=3>Level 2</td><td rowspan=1 colspan=2>1.30%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Level 3</td><td rowspan=1 colspan=2>1.44%</td><td rowspan=1 colspan=3>Level 3</td><td rowspan=1 colspan=2>1.70%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3></td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=3>Y</td><td rowspan=1 colspan=2></td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Lupus Sensitivity</td><td rowspan=1 colspan=2>CV%</td><td rowspan=1 colspan=3>Lupus Sensitivity</td><td rowspan=1 colspan=2>CV%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>EY</td><td rowspan=1 colspan=2>0.32%</td><td rowspan=1 colspan=3></td><td rowspan=1 colspan=2>1.67%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3></td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=3></td><td rowspan=1 colspan=2></td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Factor Assay</td><td rowspan=1 colspan=2>CV%</td><td rowspan=1 colspan=3>Factor Assay</td><td rowspan=1 colspan=2>CV%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Factor II</td><td rowspan=1 colspan=2>0.00%</td><td rowspan=1 colspan=3>Factor II</td><td rowspan=1 colspan=2>0.39%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Factor V</td><td rowspan=1 colspan=2>0.26%</td><td rowspan=1 colspan=3>Factor V</td><td rowspan=1 colspan=2>0.32%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Factor VII</td><td rowspan=1 colspan=2>0.19%</td><td rowspan=1 colspan=3>Factor VII</td><td rowspan=1 colspan=2>0.32%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Factor X</td><td rowspan=1 colspan=2>0.19%</td><td rowspan=1 colspan=3>Factor X</td><td rowspan=1 colspan=2>0.31%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3></td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=3>Y</td><td rowspan=1 colspan=2></td></tr><tr><td rowspan=1 colspan=1>ExpectedRange</td><td rowspan=1 colspan=5>Mean (sec)</td><td rowspan=1 colspan=5>Mean (sec)</td></tr><tr><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>1I</td><td rowspan=1 colspan=1>V</td><td rowspan=1 colspan=2>VII</td><td rowspan=1 colspan=1>X</td><td rowspan=1 colspan=1>ⅡI</td><td rowspan=1 colspan=1>V</td><td rowspan=1 colspan=2>VII</td><td rowspan=1 colspan=1>X</td></tr><tr><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>11.00</td><td rowspan=1 colspan=1>11.49</td><td rowspan=1 colspan=2>11.40</td><td rowspan=1 colspan=1>11.60</td><td rowspan=1 colspan=1>10.88</td><td rowspan=1 colspan=1>11.38</td><td rowspan=1 colspan=2>11.28</td><td rowspan=1 colspan=1>11.48</td></tr><tr><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>11.01</td><td rowspan=1 colspan=1>11.89</td><td rowspan=1 colspan=2>12.41</td><td rowspan=1 colspan=1>11.39</td><td rowspan=1 colspan=1>10.88</td><td rowspan=1 colspan=1>11.80</td><td rowspan=1 colspan=2>12.32</td><td rowspan=1 colspan=1>13.13</td></tr><tr><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>11.49</td><td rowspan=1 colspan=1>12.41</td><td rowspan=1 colspan=2>13.09</td><td rowspan=1 colspan=1>13.82</td><td rowspan=1 colspan=1>11.41</td><td rowspan=1 colspan=1>12.29</td><td rowspan=1 colspan=2>12.92</td><td rowspan=1 colspan=1>13.56</td></tr><tr><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>11.79</td><td rowspan=1 colspan=1>13.19</td><td rowspan=1 colspan=2>13.90</td><td rowspan=1 colspan=1>14.91</td><td rowspan=1 colspan=1>11.70</td><td rowspan=1 colspan=1>13.00</td><td rowspan=1 colspan=2>13.71</td><td rowspan=1 colspan=1>14.73</td></tr><tr><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>12.30</td><td rowspan=1 colspan=1>14.70</td><td rowspan=1 colspan=2>14.79</td><td rowspan=1 colspan=1>16.32</td><td rowspan=1 colspan=1>12.22</td><td rowspan=1 colspan=1>14.50</td><td rowspan=1 colspan=2>14.50</td><td rowspan=1 colspan=1>16.08</td></tr><tr><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>13.71</td><td rowspan=1 colspan=1>17.12</td><td rowspan=1 colspan=2>16.48</td><td rowspan=1 colspan=1>20.02</td><td rowspan=1 colspan=1>13.63</td><td rowspan=1 colspan=1>16.93</td><td rowspan=1 colspan=2>16.17</td><td rowspan=1 colspan=1>19.81</td></tr><tr><td rowspan=1 colspan=1></td><td></td><td></td><td></td><td></td><td></td><td rowspan=1 colspan=5></td></tr><tr><td rowspan=1 colspan=1>Linearity</td><td rowspan=1 colspan=5>11.6 36.2 sec</td><td rowspan=1 colspan=5>11.1 - 35.6 sec</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=5></td><td rowspan=1 colspan=5></td></tr><tr><td rowspan=1 colspan=1>Storage</td><td rowspan=1 colspan=5>≤-2°C</td><td rowspan=1 colspan=5>$2-8oC</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=5></td><td rowspan=1 colspan=5></td></tr><tr><td rowspan=1 colspan=1>Assay Factors</td><td rowspan=1 colspan=5>PT, Fibrinogen, Factors</td><td rowspan=1 colspan=5>PT, Fibrinogen, Factors</td></tr><tr><td rowspan=1 colspan=1>cYanmaGentaYellowb</td><td rowspan=1 colspan=5>11, V, VII, X</td><td rowspan=1 colspan=5>II, V, VII, X</td></tr></table>

# Conclusions

# Serathan-B

Wortham Laboratories Serathan-Band Pacific Hemostasis Thromboplastin-Dreagents have the same intended usc, te uniaiv eeen  the rob Te T n Factrs I, , VI, X.Boh reat preparationsofrabbit thromboplastin nd calcium chlorid, with an Interational Sensitivity ndex  .  1..

Allassays were mcasured on the fibrometer yielding a PT standard deviation of 0.0869, 0.2033 and 0.4721 for Serathan-B on Level 1, Level 2, Level 3 plasma controls, respectively, compared to Pacific Hemostasis Thromboplastin-D of 0.1050, 0.2856, 0.5467 standard deviation on the same controls.

Comparing he preision he oreagents inhefcr assays prouce a andard deviation f0.03, .00.022 and 0.022 for Factors I V, V1 X, respeivly for Serathan-B, contrasted to 0.043, 0.036, 0.036, and 0.036 for Thromboplastin-D.

Reproducibility of the two reagents yielded a $0 . 8 0 \%$ within-run coefficient of variation and a run-run $0 . 7 5 \%$ CV for Serathan-B, compared respectively to the predicate control of $0 . 9 1 \%$ CV and $0 . 8 9 \%$ CV.

The poae data prent hre s w as heunistinguishabltenusen tehnologicalar support the substantial equivalence claim for Wortham Laboratories Serathan-B to Pacific Hemostasis Throoplastin-DBason the data provides ur conclusion that these wo products aresustntly equivalent.

# Wortham Laboratories, Inc.

K060968

# Premarket Notification 510 (k) Summary

# Serathan-A PT Reagent

The assigned 510K number is: K060968

# Applicant:

Wortham Laboratories, Inc. 6340 Bonny Oaks Dr Chattanooga, TN 37416 Tel: (423) 296-0090 Fax: (423) 296-0188

# Contact:

Lcon Wortham

# Date:

April 6, 2007

# Device Name:

Wortham Laboratories Serathan-A PT Rcagent.

# Common Name:

Prothrombin Time

Classification Name:

Prothrombin Time Test, is a class II device, as per 21 CFR 864.7750 (Product Code GjS). This device is intended for clinical use in conjunction with an analyzer to measure clot formation.

# Predicate:

Pacific Hemostasis Thromboplastin-DS (K940082)

# Description

WoraLSathn Rat islqu tabletr rab lastlc, stabilizerand buffer.Serathan-A is an in-vitro diagnosticreagent intended for use for the perormanc Prothrombin Time (PT) testing and quantitative PT-based factor assays for Factors II, V. VII and X.

# Intended Use

Wortham Laboratr Seathan-A PT reagent is nin-virodiaosticatntende in clinical labora t iv uat lt extrinsic pathway. Serathan-A is a highly sensitive thromboplastin reagent.

# Labeling

This device is labeled in accordance with 21 CFR 801.

# Substantial Equivalence

<table><tr><td rowspan=1 colspan=1>CharacteristicsIntended Usc</td><td rowspan=1 colspan=5>New DevicePerformance of Prothrombin Time (PT) testingfor the detection of coagulation abnormalities inthe extrinsic pathway</td><td rowspan=1 colspan=5>PredicatePerfornance of Prothrombin Time (PT)testing for the detection of coagulationabnormalities in the extrinsic pathway</td></tr><tr><td rowspan=1 colspan=1></td><td></td><td></td><td></td><td></td><td></td><td rowspan=1 colspan=5>Y</td></tr><tr><td rowspan=1 colspan=1>ReagentComposition</td><td rowspan=1 colspan=5>Liquid Rabbit Thromboplastin</td><td rowspan=1 colspan=5>Lypholyzed Rabbit Thromboplastin</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=5>Y</td><td rowspan=1 colspan=5>Y</td></tr><tr><td rowspan=1 colspan=1>Stability</td><td rowspan=1 colspan=5>12 months @ ≤ -2°C30 days @ 2-4° C</td><td rowspan=1 colspan=5>30 months @ 2-8° C, lypholyzed7 days @ 2-8° C, rehydrated</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=5>Y</td><td rowspan=1 colspan=5>Y</td></tr><tr><td rowspan=1 colspan=1>ReferenceValues</td><td rowspan=1 colspan=3>within-run</td><td rowspan=1 colspan=2>CV%</td><td rowspan=1 colspan=3>within-run</td><td rowspan=1 colspan=2>CV %</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Levcl 1</td><td rowspan=1 colspan=2>0.89%</td><td rowspan=1 colspan=3>Level 1</td><td rowspan=1 colspan=2>1.36%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Level 2</td><td rowspan=1 colspan=2>1.09%</td><td rowspan=1 colspan=3>Level 2</td><td rowspan=1 colspan=2>1.28%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Level 3</td><td rowspan=1 colspan=2>1.25%</td><td rowspan=1 colspan=3>Level 3</td><td rowspan=1 colspan=2>1.52%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3></td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=3>Y</td><td rowspan=1 colspan=2></td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>run-run</td><td rowspan=1 colspan=2>CV%</td><td rowspan=1 colspan=3>run-run</td><td rowspan=1 colspan=2>CV%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Level 1</td><td rowspan=1 colspan=2>0.88%</td><td rowspan=1 colspan=3>Level 1</td><td rowspan=1 colspan=2>1.38%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Levcl 2</td><td rowspan=1 colspan=2>1.08%</td><td rowspan=1 colspan=3>Level 2</td><td rowspan=1 colspan=2>1.19%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Level 3</td><td rowspan=1 colspan=2>1.28%</td><td rowspan=1 colspan=3>Level 3</td><td rowspan=1 colspan=2>1.58%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Y</td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=3>Y</td><td rowspan=1 colspan=2></td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Lupus Sensitivity</td><td rowspan=1 colspan=2>CV%</td><td rowspan=1 colspan=3>Lupus Sensitivity</td><td rowspan=1 colspan=2>CV%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3></td><td rowspan=1 colspan=2>0.29%</td><td rowspan=1 colspan=3>Y</td><td rowspan=1 colspan=2>2.04%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Y</td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=3></td><td rowspan=1 colspan=2></td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Factor Assay</td><td rowspan=1 colspan=2>CV%</td><td rowspan=1 colspan=3>Factor Assay</td><td rowspan=1 colspan=2>CV%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Factor II</td><td rowspan=1 colspan=2>1.25%</td><td rowspan=1 colspan=3>Factor II</td><td rowspan=1 colspan=2>0.42%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Factor V</td><td rowspan=1 colspan=2>0.25%</td><td rowspan=1 colspan=3>Factor V</td><td rowspan=1 colspan=2>0.37%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Factor VII</td><td rowspan=1 colspan=2>0.25%</td><td rowspan=1 colspan=3>Factor VII</td><td rowspan=1 colspan=2>0.38%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Factor X</td><td rowspan=1 colspan=2>0.18%</td><td rowspan=1 colspan=3>Factor X</td><td rowspan=1 colspan=2>0.32%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3></td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=3></td><td rowspan=1 colspan=2></td></tr><tr><td rowspan=1 colspan=1>ExpectedRange</td><td rowspan=1 colspan=5>Mean (sec)</td><td rowspan=1 colspan=5>Mean (sec)</td></tr><tr><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>II</td><td rowspan=1 colspan=1>V</td><td rowspan=1 colspan=2>VII</td><td rowspan=1 colspan=1>X</td><td rowspan=1 colspan=1>II</td><td rowspan=1 colspan=1>V</td><td rowspan=1 colspan=2>VII</td><td rowspan=1 colspan=1>X</td></tr><tr><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>11.79</td><td rowspan=1 colspan=1>11.79</td><td rowspan=1 colspan=2>11.99</td><td rowspan=1 colspan=1>11.90</td><td rowspan=1 colspan=1>11.69</td><td rowspan=1 colspan=1>11.67</td><td rowspan=1 colspan=2>11.90</td><td rowspan=1 colspan=1>11.80</td></tr><tr><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>11.80</td><td rowspan=1 colspan=1>13.41</td><td rowspan=1 colspan=2>12.79</td><td rowspan=1 colspan=1>13.11</td><td rowspan=1 colspan=1>11.72</td><td rowspan=1 colspan=1>13.31</td><td rowspan=1 colspan=2>12.70</td><td rowspan=1 colspan=1>12.98</td></tr><tr><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>12.02</td><td rowspan=1 colspan=1>14.20</td><td rowspan=1 colspan=2>12.98</td><td rowspan=1 colspan=1>13.60</td><td rowspan=1 colspan=1>11.92</td><td rowspan=1 colspan=1>14.09</td><td rowspan=1 colspan=2>12.92</td><td rowspan=1 colspan=1>13.51</td></tr><tr><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>12.38</td><td rowspan=1 colspan=1>15.20</td><td rowspan=1 colspan=2>13.82</td><td rowspan=1 colspan=1>14.52</td><td rowspan=1 colspan=1>12.30</td><td rowspan=1 colspan=1>15.13</td><td rowspan=1 colspan=2>13.72</td><td rowspan=1 colspan=1>14.38</td></tr><tr><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>12.99</td><td rowspan=1 colspan=1>16.29</td><td rowspan=1 colspan=2>14.11</td><td rowspan=1 colspan=1>15.21</td><td rowspan=1 colspan=1>12.80</td><td rowspan=1 colspan=1>16.22</td><td rowspan=1 colspan=2>14.02</td><td rowspan=1 colspan=1>15.10</td></tr><tr><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>14.31</td><td rowspan=1 colspan=1>18.66</td><td rowspan=1 colspan=2>15.51</td><td rowspan=1 colspan=1>17.52</td><td rowspan=1 colspan=1>14.02</td><td rowspan=1 colspan=1>18.48</td><td rowspan=1 colspan=2>15.38</td><td rowspan=1 colspan=1>17.30</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=5></td><td rowspan=1 colspan=5></td></tr><tr><td rowspan=1 colspan=1>Lincarity</td><td rowspan=1 colspan=5>12.1-41.9 sec</td><td rowspan=1 colspan=5>11.9 -41.1 sec</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=5></td><td rowspan=1 colspan=5></td></tr><tr><td rowspan=1 colspan=1>Storage</td><td rowspan=1 colspan=5>≤-2°C</td><td rowspan=1 colspan=5>2-8oC</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=5></td><td rowspan=1 colspan=5></td></tr><tr><td rowspan=1 colspan=1>Assay Factors</td><td rowspan=1 colspan=5>PT, Fibrinogen, Factors</td><td rowspan=1 colspan=5>PT, Fibrinogen, Factors</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=5>II, V, VII, X</td><td rowspan=1 colspan=5>II, V, VII, X</td></tr></table>

# Conclusions

# Serathan-A

Wortham Laboratories Serathan-A and Pacific Hemostasis Thromboplastin-DS ragents have the same intendeduse, s r the quantiative esrement f the rohrombin Tme T), and Factrs II, V, VII, X.Both reaget e preparations orabbit throboplastn nd calciumchlori, with an Interational Sensitivityndex f .1.

All assays were measured on the fibromcter yiclding a PT standard deviation of 0.1135, 0.3977 and 0.7746 for Serathan-A on Level 1, Level 2, Level 3 plasma controls, respectively, compared to Pacific Hemostasis Thromboplastin-DS of 0.1694, 0.4320, 0.8556 standard deviation on the same controls.

Comparing the precision of the two reagents in the factor assays produced a standard deviation f 0.030, 0.030, 0.0and0.022 r Factors I V, VII, X, vely r SahA, corae o0.04970.04, 0.045, an 0.038 for Thromboplastin-DS.

Reproducibility of the two reagents yiclded a $1 . 0 9 \%$ within-run coefficient of variation and a run-run $0 . 9 7 \%$ CV for Serathan-A, compared respectively to the predicate control of $1 . 1 8 \%$ CV and $1 . 2 1 \%$ CV.

The et pnhe   as eingishabtenunnolgil support the substantial equivalence claim for Wortham Laboratories Serathan-A to Pacific Hemostasis Trooplast-D.Bas n he ata provie i is ur conclusion that hesetwo proucts are sustnlly equivalent.

# Wortham Laboratories, Inc.

MAY 15 2007

# Premarket Notification 510 (k) Summary

# Intrin-EA APTT Reagent

The assigned 510K number is: K060968

# Applicant:

Wortham Laboratories, Inc. 6340 Bonny Oaks Dr Chattanooga, TN 37416 Tel: (423) 296-0090 Fax: (423) 296-0188

# Contact:

Leon Wortham

# Date:

April 6, 2007

# Device Name:

Wortham Laboratorics Intrin-EA APTT Reagent.

# Common Name:

Activated Partial Thromboplastin Time (APTT)

Classification Name:

Activated Partial Thromboplastin is a class II device, as per 21 CFR 864.7925 (Product Code GFO). This device is intended for clinical use in conjunction with an analyzer to measure clot formation.

# Predicate:

Pacific Hemostasis APTT-LS (K891337)

# Description

Worhm Laboraor Intrin-AAPTT eantntr usnetectivat paral rlas tm (T) and coagulatn facto assays that re based on a modid AT.The capaciy  blood to r a f ot  we cr XI XI, IX,pa al  a e ellagic acid.

# Intended Use

Wortham Laboratories Intrin-EA APTT is an in-vitro diagnostic ragent used in the clinical laboratory or the tiecva rlas abnormalities in the intrinsic pathway. Intrin-EA reagent is sensitivc to mild coagulopathies.

# Labcling

This device is labeled in accordance with 21 CFR 801.

<table><tr><td rowspan=1 colspan=11>Substantial Equivalence</td></tr><tr><td rowspan=1 colspan=1>CharacteristicsIntended Use</td><td rowspan=1 colspan=5>New DevicePerformance of Activated PartialThromboplastin Time (APTT) testing for thedetection of coagulation abnormalities in theintrinsic pathway</td><td rowspan=1 colspan=5>PredicatePerformance of Activated Partial ThromboplastinTime (APTT) testing for the detection ofcoagulation abnormalities in the intrinsic pathway</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=5></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td rowspan=1 colspan=1>ReagentComposition</td><td rowspan=1 colspan=5>Liquid Rabbit Thromboplastin with ellagicacid activator</td><td rowspan=1 colspan=5>Liquid Rabbit Thromboplastin with ellagic acidactivator</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=5></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td rowspan=1 colspan=1>Stability</td><td rowspan=1 colspan=5>12 months @ ≤ -2° C30 days @ 2-4° C</td><td rowspan=1 colspan=5>22 months @ 2-8° C, lypholyzed30 days @ 2-8° C, rehydrated</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3></td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=3></td><td rowspan=1 colspan=2>Y</td></tr><tr><td rowspan=1 colspan=1>ReferenceValues</td><td rowspan=1 colspan=3>within-run</td><td rowspan=1 colspan=2>CV%</td><td rowspan=1 colspan=3>within-run</td><td rowspan=1 colspan=2>CV%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Level 1</td><td rowspan=1 colspan=2>0.51%</td><td rowspan=1 colspan=3>Levcl 1</td><td rowspan=1 colspan=2>0.85%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Level 2</td><td rowspan=1 colspan=2>0.41%</td><td rowspan=1 colspan=3>Level 2</td><td rowspan=1 colspan=2>0.91%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Level 3</td><td rowspan=1 colspan=2>0.73%</td><td rowspan=1 colspan=3>Level 3</td><td rowspan=1 colspan=2>1.12%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3></td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=3></td><td rowspan=1 colspan=2>Y</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>run-run</td><td rowspan=1 colspan=2>CV%</td><td rowspan=1 colspan=3>run-run</td><td rowspan=1 colspan=2>CV%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Level 1</td><td rowspan=1 colspan=2>0.51%</td><td rowspan=1 colspan=3>Level 1</td><td rowspan=1 colspan=2>0.85%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Level 2</td><td rowspan=1 colspan=2>0.44%</td><td rowspan=1 colspan=3>Level 2</td><td rowspan=1 colspan=2>0.90%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Level 3</td><td rowspan=1 colspan=2>0.71%</td><td rowspan=1 colspan=3>Level 3</td><td rowspan=1 colspan=2>1.11%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3></td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=3></td><td rowspan=1 colspan=2></td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Heparin Sensitivity</td><td rowspan=1 colspan=2>CV%</td><td rowspan=1 colspan=3>Heparin Sensitivity</td><td rowspan=1 colspan=2>CV%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>0.25 U/ml</td><td rowspan=1 colspan=2>0.71%</td><td rowspan=1 colspan=3>0.25 U/ml</td><td rowspan=1 colspan=2>1.03%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>0.35 U/ml</td><td rowspan=1 colspan=2>0.54%</td><td rowspan=1 colspan=3>0.35 U/ml</td><td rowspan=1 colspan=2>0.91%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Y</td><td rowspan=1 colspan=2>Y</td><td rowspan=1 colspan=3></td><td rowspan=1 colspan=2></td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Lupus Sensitivity</td><td rowspan=1 colspan=2>CV%</td><td rowspan=1 colspan=3>Lupus Sensitivity</td><td rowspan=1 colspan=2>CV%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Y</td><td rowspan=1 colspan=2>4.39%</td><td rowspan=1 colspan=3></td><td rowspan=1 colspan=2>7.81%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3></td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=3></td><td rowspan=1 colspan=2></td></tr><tr><td rowspan=1 colspan=1>cYanmaGentaYelowb</td><td rowspan=1 colspan=3>Factor Assay</td><td rowspan=1 colspan=2>CV%</td><td rowspan=1 colspan=3>Factor Assay</td><td rowspan=1 colspan=2>CV%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Factor VIII</td><td rowspan=1 colspan=2>0.17%</td><td rowspan=1 colspan=3>Factor VIII</td><td rowspan=1 colspan=2>0.23%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Factor IX</td><td rowspan=1 colspan=2>0.17%</td><td rowspan=1 colspan=3>Factor IX</td><td rowspan=1 colspan=2>0.24%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Factor XI</td><td rowspan=1 colspan=2>0.14%</td><td rowspan=1 colspan=3>Factor XI</td><td rowspan=1 colspan=2>0.29%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Factor XII</td><td rowspan=1 colspan=2>0.13%</td><td rowspan=1 colspan=3>Factor XII</td><td rowspan=1 colspan=2>0.26%</td></tr><tr><td rowspan=1 colspan=1>cYanmaGGentaYellowb</td><td rowspan=1 colspan=5></td><td rowspan=1 colspan=5></td></tr><tr><td rowspan=1 colspan=1>ExpectedRange</td><td rowspan=1 colspan=5>Mean (sec)</td><td rowspan=1 colspan=5>Mean (sec)</td></tr><tr><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>VIII</td><td rowspan=1 colspan=1>IX</td><td rowspan=1 colspan=2>XI</td><td rowspan=1 colspan=1>XII</td><td rowspan=1 colspan=1>VIII</td><td rowspan=1 colspan=1>IX</td><td rowspan=1 colspan=2>XI</td><td rowspan=1 colspan=1>XII</td></tr><tr><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>29.36</td><td rowspan=1 colspan=1>28.54</td><td rowspan=1 colspan=2>29.47</td><td rowspan=1 colspan=1>26.82</td><td rowspan=1 colspan=1>28.23</td><td rowspan=1 colspan=1>27.48</td><td rowspan=1 colspan=2>28.32</td><td rowspan=1 colspan=1>25.78</td></tr><tr><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>33.86</td><td rowspan=1 colspan=1>32.38</td><td rowspan=1 colspan=2>34.74</td><td rowspan=1 colspan=1>29.89</td><td rowspan=1 colspan=1>32.57</td><td rowspan=1 colspan=1>31.26</td><td rowspan=1 colspan=2>33.36</td><td rowspan=1 colspan=1>28.65</td></tr><tr><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>35.08</td><td rowspan=1 colspan=1>34.03</td><td rowspan=1 colspan=2>36.26</td><td rowspan=1 colspan=1>31.14</td><td rowspan=1 colspan=1>33.83</td><td rowspan=1 colspan=1>33.02</td><td rowspan=1 colspan=2>35.03</td><td rowspan=1 colspan=1>29.78</td></tr><tr><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>37.33</td><td rowspan=1 colspan=1>36.34</td><td rowspan=1 colspan=2>38.61</td><td rowspan=1 colspan=1>32.23</td><td rowspan=1 colspan=1>36.13</td><td rowspan=1 colspan=1>35.12</td><td rowspan=1 colspan=2>37.30</td><td rowspan=1 colspan=1>31.09</td></tr><tr><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>40.47</td><td rowspan=1 colspan=1>38.64</td><td rowspan=1 colspan=2>41.35</td><td rowspan=1 colspan=1>33.33</td><td rowspan=1 colspan=1>39.20</td><td rowspan=1 colspan=1>37.40</td><td rowspan=1 colspan=2>40.14</td><td rowspan=1 colspan=1>32.07</td></tr><tr><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>45.10</td><td rowspan=1 colspan=1>40.89</td><td rowspan=1 colspan=2>46.84</td><td rowspan=1 colspan=1>35.04</td><td rowspan=1 colspan=1>43.78</td><td rowspan=1 colspan=1>39.86</td><td rowspan=1 colspan=2>45.70</td><td rowspan=1 colspan=1>33.21</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=5></td><td rowspan=1 colspan=5></td></tr><tr><td rowspan=1 colspan=1>Linearity</td><td rowspan=1 colspan=5>29.0 - 70.7 sec</td><td rowspan=1 colspan=5>28.5 - 69.6 sec</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=5></td><td rowspan=1 colspan=5></td></tr><tr><td rowspan=1 colspan=1>Storage</td><td rowspan=1 colspan=5>≤-2oC</td><td rowspan=1 colspan=5>2-8oC</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=5></td><td rowspan=1 colspan=5></td></tr><tr><td rowspan=1 colspan=1>Assay Factors</td><td rowspan=1 colspan=5>APTT, Heparin, Factors</td><td rowspan=1 colspan=5>APTT, Heparin, Factors</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=5>VIII, IX, XI, XII</td><td rowspan=1 colspan=5>VIII, IX, XI, XII</td></tr></table>

# Conclusions

Intrin-EA

Wortha Laborators Intri-EA nd Paci Hemstasi PTT-LS reagents have he smenuse, s rhe qanativemet  thectivate artalroboplastnme TT, Hepari, andFactorsVI, IX, XI, XII. Both reagents are preparations of rabbit thromboplastin and efllagic acid as an activator.

All asays weremeasur on the fbromeer yielding an APTT standard deviation of 0.1483, 0.1968 and 0.4961 for Intrin-EA on Level 1, Level2, Level 3 plasa control, respectively, compared to PaciicHemostasis APTT-LS 0.1908, 0.4030, 0.8900 standard deviation on the same controls.

Intrin-EA sensitivity to heparin at $0 . 2 5 ~ \mathrm { U / m l }$ and $0 . 3 5 \ : \mathrm { U / m l }$ , yielded a 0.2236 standard deviation to both levels of heparin compared to 0.3078 and 0.3664 standard deviation, respectively, in the predicate product.

Comparing the precision of the two reagents in the fctor assays produce a standard deviation  0.049, 0.048, 0.043, and 0.036 SD for Factors VIII IX, XI, XII, respetively for Intrin-EA, to 0.064, 0.065, 0.083, and 0.068 SD for APTT-LS.

Reproducibility of the two reagents yielded a $0 . 7 1 \%$ coefficient of variation at $0 . 2 5 \mathrm { U } / \mathrm { m l }$ and $0 . 5 4 \%$ CV at 0.35 $\mathrm { U } / { \mathfrak { m } } \mathfrak { k }$ heparin, compared to APTT-LS $1 . 0 3 \%$ CV and $0 . 9 1 \%$ CV, respectively.

The peora datpresnthere s we as tendisinguishabltenduse nd teologicalharcc support the substantial equivalence claim for Wortham Laboratories Intrin-EA to Pacific Hemostasis APTT-LS. Bascd on the data provided, it is our conclusion that these two products are substantially equivalent.

# Wortham Laboratories, Inc.

MAY 15 2007

# Premarket Notification 510 (k) Summary

Intrin-SI APTT Reagent

The assigned 510K number is: K060968

# Applicant:

Wortham Laboratories, Inc. 6340 Bonny Oaks Dr Chattanooga, TN 37416 Tel: (423) 296-0090 Fax: (423) 296-0188

# Contact:

Lcon Wortham

# Date:

April 6, 2007

Device Name:

Wortham Laboratories Intrin-SI APTT Reagent is a liquid stable extract of rabbit brain thromboplastin, containing stabilizers and buffers. Intrin-SI is an in-vitro diagnostic reagent intended for use for the performance of a citrated Partial Thromboplastin Time (APTT) testing and quantitative PTT-based factor assays for Factors XII, XI, IX and VIII.

# Common Name:

Activated Partial Thromboplastin Time (APTT)

Classification Name:

Activated Partial Thromboplastin is a class II device, as pcr 21 CFR 864.7925 (Product Code GFO). This devicc is intended for clinical use in conjunction with an analyzer to measure clot formation.

# Predicate:

Pacific Hemostasis Kontact (K023362)

# Description

Wor Lo IntSTT ntntnerusti ctivat parlhra t (PTT) and coagulatn factor assays that ae base on a modid ATT.The capacity  blood to r a co y    ucr I, IX,VI at calce   a  e Kaolin.

# Intended Use

W  nS  l determination of Activated Partial Thromboplastin Time (APTT) testing for the detection of coagulation alheayI t  sivhep uu p.

# Labeling

This device is labeled in accordance with 21 CFR 801.

<table><tr><td rowspan=1 colspan=1>CharacteristicsIntended Use</td><td rowspan=1 colspan=5>New DevicePerformance of Activated PartialThromboplastin Time (APTT) testing for thedetection of coagulation abnornalities in theintrinsic pathway</td><td rowspan=1 colspan=5>PredicatePerformance of Activated PartialThromboplastin Time (APTT) testing for thedetection of coagulation abnormalities in theintrinsic pathway</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=5></td><td rowspan=1 colspan=5></td></tr><tr><td rowspan=1 colspan=1>ReagentComposition</td><td rowspan=1 colspan=5>Liquid Rabbit Thromboplastin with a siliconactivator</td><td rowspan=1 colspan=5>Liquid Rabbit Thromboplastin with a siliconactivator</td></tr><tr><td rowspan=1 colspan=1></td><td></td><td></td><td></td><td></td><td></td><td rowspan=1 colspan=5></td></tr><tr><td rowspan=1 colspan=1>Stability</td><td rowspan=1 colspan=5>12 months @ ≤ -2° C30 days @ 2-4° C</td><td rowspan=1 colspan=5>12 months @ 2-8° C30 days @ 2-8° C, open</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>E</td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=3>Y</td><td rowspan=1 colspan=2></td></tr><tr><td rowspan=1 colspan=1>ReferenceValues</td><td rowspan=1 colspan=3>within-run</td><td rowspan=1 colspan=2>CV%</td><td rowspan=1 colspan=3>within-run</td><td rowspan=1 colspan=2>CV%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Level I</td><td rowspan=1 colspan=2>0.29%</td><td rowspan=1 colspan=3>Level 1</td><td rowspan=1 colspan=2>1.54%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Level 2</td><td rowspan=1 colspan=2>0.74%</td><td rowspan=1 colspan=3>Level 2</td><td rowspan=1 colspan=2>1.00%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Level 3</td><td rowspan=1 colspan=2>0.75%</td><td rowspan=1 colspan=3>Level 3</td><td rowspan=1 colspan=2>1.16%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3></td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=3>Y</td><td rowspan=1 colspan=2></td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>run-run</td><td rowspan=1 colspan=2>CV%</td><td rowspan=1 colspan=3>run-run</td><td rowspan=1 colspan=2>CV %</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Level 1</td><td rowspan=1 colspan=2>0.29%</td><td rowspan=1 colspan=3>Level 1</td><td rowspan=1 colspan=2>1.20%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Level 2</td><td rowspan=1 colspan=2>0.75%</td><td rowspan=1 colspan=3>Level 2</td><td rowspan=1 colspan=2>1.01%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Level 3</td><td rowspan=1 colspan=2>0.75%</td><td rowspan=1 colspan=3>Level 3</td><td rowspan=1 colspan=2>1.15%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3></td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=3></td><td rowspan=1 colspan=2></td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Heparin Sensitivity</td><td rowspan=1 colspan=2>CV%</td><td rowspan=1 colspan=3>Heparin Sensitivity</td><td rowspan=1 colspan=2>CV%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>0.25 U/ml</td><td rowspan=1 colspan=2>1.57%</td><td rowspan=1 colspan=3>0.25 U/ml</td><td rowspan=1 colspan=2>2.30%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>0.35 U/ml</td><td rowspan=1 colspan=2>1.53%</td><td rowspan=1 colspan=3>0.35 U/ml</td><td rowspan=1 colspan=2>2.02%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3></td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=3></td><td rowspan=1 colspan=2></td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Lupus Sensitivity</td><td rowspan=1 colspan=2>CV%</td><td rowspan=1 colspan=3>Lupus Sensitivity</td><td rowspan=1 colspan=2>CV%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3></td><td rowspan=1 colspan=2>6.37%</td><td rowspan=1 colspan=3></td><td rowspan=1 colspan=2>16.80%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3></td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=3></td><td rowspan=1 colspan=2></td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Factor Assay</td><td rowspan=1 colspan=2>CV%</td><td rowspan=1 colspan=3>Factor Assay</td><td rowspan=1 colspan=2>CV%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Factor VIII</td><td rowspan=1 colspan=2>0.13%</td><td rowspan=1 colspan=3>Factor VIII</td><td rowspan=1 colspan=2>0.31%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Factor IX</td><td rowspan=1 colspan=2>0.10%</td><td rowspan=1 colspan=3>Factor IX</td><td rowspan=1 colspan=2>0.32%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Factor XI</td><td rowspan=1 colspan=2>0.16%</td><td rowspan=1 colspan=3>Factor XI</td><td rowspan=1 colspan=2>0.26%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Factor XII</td><td rowspan=1 colspan=2>0.18%</td><td rowspan=1 colspan=3>Factor XII</td><td rowspan=1 colspan=2>0.34%</td></tr><tr><td rowspan=1 colspan=1></td><td></td><td></td><td></td><td></td><td></td><td rowspan=1 colspan=5></td></tr><tr><td rowspan=1 colspan=1>ExpectedRange</td><td rowspan=1 colspan=5>Mean (sec)</td><td rowspan=1 colspan=5>Mean (sec)</td></tr><tr><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>VIIII</td><td rowspan=1 colspan=1>IX</td><td rowspan=1 colspan=2>XI</td><td rowspan=1 colspan=1>XII</td><td rowspan=1 colspan=1>VIII</td><td rowspan=1 colspan=1>IX</td><td rowspan=1 colspan=2>XI</td><td rowspan=1 colspan=1>XII</td></tr><tr><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>28.52</td><td rowspan=1 colspan=1>29.59</td><td rowspan=1 colspan=2>29.17</td><td rowspan=1 colspan=1>28.56</td><td rowspan=1 colspan=1>27.85</td><td rowspan=1 colspan=1>28.12</td><td rowspan=1 colspan=2>28.05</td><td rowspan=1 colspan=1>27.78</td></tr><tr><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>34.77</td><td rowspan=1 colspan=1>34.77</td><td rowspan=1 colspan=2>32.78</td><td rowspan=1 colspan=1>30.35</td><td rowspan=1 colspan=1>33.75</td><td rowspan=1 colspan=1>34.08</td><td rowspan=1 colspan=2>31.38</td><td rowspan=1 colspan=1>29.26</td></tr><tr><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>38.02</td><td rowspan=1 colspan=1>38.02</td><td rowspan=1 colspan=2>35.80</td><td rowspan=1 colspan=1>34.23</td><td rowspan=1 colspan=1>36.14</td><td rowspan=1 colspan=1>37.21</td><td rowspan=1 colspan=2>34.80</td><td rowspan=1 colspan=1>33.13</td></tr><tr><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>42.31</td><td rowspan=1 colspan=1>42.61</td><td rowspan=1 colspan=2>39.57</td><td rowspan=1 colspan=1>37.83</td><td rowspan=1 colspan=1>40.90</td><td rowspan=1 colspan=1>41.74</td><td rowspan=1 colspan=2>38.52</td><td rowspan=1 colspan=1>36.64</td></tr><tr><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>49.91</td><td rowspan=1 colspan=1>50.22</td><td rowspan=1 colspan=2>46.00</td><td rowspan=1 colspan=1>41.59</td><td rowspan=1 colspan=1>47.22</td><td rowspan=1 colspan=1>49.16</td><td rowspan=1 colspan=2>45.15</td><td rowspan=1 colspan=1>40.31</td></tr><tr><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>57.21</td><td rowspan=1 colspan=1>56.14</td><td rowspan=1 colspan=2>53.68</td><td rowspan=1 colspan=1>48.83</td><td rowspan=1 colspan=1>54.18</td><td rowspan=1 colspan=1>55.12</td><td rowspan=1 colspan=2>52.32</td><td rowspan=1 colspan=1>47.67</td></tr><tr><td rowspan=1 colspan=1></td><td></td><td></td><td></td><td></td><td></td><td rowspan=1 colspan=5></td></tr><tr><td rowspan=1 colspan=1>Storage</td><td rowspan=1 colspan=5>≤-2°C</td><td rowspan=1 colspan=5>2-8oC</td></tr><tr><td rowspan=1 colspan=1></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td rowspan=1 colspan=1>Assay Factors</td><td rowspan=1 colspan=5>APTT, Heparin, Factors</td><td rowspan=1 colspan=5>APTT, Heparin, Factors</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=5>VIII, IX, XI, XII</td><td rowspan=1 colspan=5>VIII, IX, XI, XII</td></tr></table>

# Conclusions

Intrin-S1

Wortham Laboratories Intrin-SI and Pacific Hemostasis Kontact ragents have the same intended use, as for the qnaivesrement  the ctivate artl robolase T, Hepari, and FctorsV IX, XI, XII. Both reagents arc preparations of rabbit thromboplastin and a silicon activator from kaolin.

All assys wer mcasured on thefibromeer yielding an APTT standard deviation of 0.0863, 0.4135 and 0.5278 for Intrin-SI on Level 1, Level 2, Level 3 plasma controls, respectively, compared to PaciicHemostasis Kontac o 0.1989, 0.5721, 0.6465 standard deviation on the same controls.

Intrin-SI sensitivity to heparin at $0 . 2 5 ~ \mathrm { U / m l }$ and $0 . 3 5 ~ \mathrm { U / m l }$ , yielded a 0.2236 standard deviation to both levels of heparin compared to 0.3078 and 0.3664 standard deviation, respectively, in the predicate product.

Comparing the precision of the two reagents in the fctorassays produced a standard deviation of 0.036, 0.030 0.0 and 0.050 SD or Facors VII, IX, XI, XI, espeively for Intrin-SI, to 0.087, 0.089, 0.074, and 0.096 SD for Kontact.

Reproducibility of the two rcagents yiclded a $0 . 6 7 \%$ coefficient of variation at $0 . 2 5 ~ \mathrm { U / m l }$ and $0 . 4 8 \%$ CV at 0.35 U/iml heparin, compared to Kontact $0 . 9 4 \%$ CV and $0 . 7 2 \%$ CV, respectively.

The p ata pren re  w as henisingushabltendeuse n teologilar suprt the substantial equivalence claim orWortham Laboratoris Intrin-S to PaciiHmostasis ontactas on the data provided, it is our conclusion that these two products are substantially equivalent.

# Wortham Laboratories, Inc.

# Premarket Notification 510 (k) Summary

Fibrinogen Control Plasma

The assigned 510K number is: K060968

# Applicant:

Wortham Laboratories, Inc. 6340 Bonny Oaks Dr Chattanooga, TN 37416 Tel: (423) 296-0090 Fax: (423) 296-0188

# Contact:

Leon Wortham

# Date:

April 6, 2007

# Device Name:

Wortham Laboratories Fibrinogen Control Plasma (Low).

# Common Name:

Fibrinogen Control Plasma

Classification Name:

Plasma, Coagulation Control, is a class II device as pcr 21 CFR 864.5425 (Product Code GHH). This device is intended for clinical use in conjunction with an analyzer to measure clot formation.

# Predicate:

Pacific Hemostasis Fibrinogen Assay (K800826)

# Description

Wortham Laboratories Fibrinogen Low Control is a liquid stable preparation of citrated plasma obtained from h ue control has been tested by an FDA approved method and found non-reactiv or HBsAg and negativeor antiodis to HIV and HCV.

# Intended Use

Woram Labotri Fibrioen Control Low a quantitativcontol plasa is ten or ue  the ay control of fibrinogen assays.

# Labeling

This device is labeled in accordance with 21 CFR 801.

# Substantial Equivalence

<table><tr><td rowspan=1 colspan=1>CharacteristicsIntended Use</td><td rowspan=1 colspan=4>New DeviceTo determine quantitative level of fibrinogen inplasma sample, and for quality control inmonitoring heparin therapy with APTT testing</td><td rowspan=1 colspan=3>PredicateTo determine quantitative level of fibrinogenin plasma sample, and for quality control inmonitoring heparin therapy with APTTtesting</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=4>cYanmaGentntntaYellowb</td><td rowspan=1 colspan=3></td></tr><tr><td rowspan=1 colspan=1>ControlComposition</td><td rowspan=1 colspan=4>Liquid Human citrated plasma</td><td rowspan=1 colspan=3>Lypholyzed Hunan citrated plasma</td></tr><tr><td rowspan=1 colspan=1></td><td></td><td></td><td></td><td></td><td rowspan=1 colspan=3></td></tr><tr><td rowspan=1 colspan=1>Stability</td><td rowspan=1 colspan=4>12 months @ ≤ -2°C30 days @ 2-4° C</td><td rowspan=1 colspan=3>24 months @ 2-8° C, lypholyzed16 hours @ 2-8° C, rehydrated</td></tr><tr><td rowspan=1 colspan=1></td><td></td><td></td><td></td><td></td><td rowspan=1 colspan=3></td></tr><tr><td rowspan=1 colspan=1>ReferenceValues</td><td rowspan=1 colspan=3>within-run</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=2>within-run</td><td rowspan=1 colspan=1>CV%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Normal</td><td rowspan=1 colspan=1>0.56%</td><td rowspan=1 colspan=2>Normal</td><td rowspan=1 colspan=1>0.59%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Low</td><td rowspan=1 colspan=1>0.60%</td><td rowspan=1 colspan=2>Low</td><td rowspan=1 colspan=1>0.63%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>run-run</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=2>run-run</td><td rowspan=1 colspan=1>CV%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Normal</td><td rowspan=1 colspan=1>0.57%</td><td rowspan=1 colspan=2>Normal</td><td rowspan=1 colspan=1>0.60%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Low</td><td rowspan=1 colspan=1>0.58%</td><td rowspan=1 colspan=2>Low</td><td rowspan=1 colspan=1>0.67%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Expected Range</td><td rowspan=1 colspan=1>Mechanical</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=2>±2SD</td><td rowspan=1 colspan=1>Mechanical</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>±2SD</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Normal</td><td rowspan=1 colspan=1>306.3</td><td rowspan=1 colspan=2>301-313 g/dl</td><td rowspan=1 colspan=1>Normal</td><td rowspan=1 colspan=1>306.3</td><td rowspan=1 colspan=1>297-315 g/dl</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Low</td><td rowspan=1 colspan=1>99.1</td><td rowspan=1 colspan=2>97-103 g/dl</td><td rowspan=1 colspan=1>Low</td><td rowspan=1 colspan=1>99.8</td><td rowspan=1 colspan=1>97-104 g/dl</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=4></td><td rowspan=1 colspan=3></td></tr><tr><td rowspan=1 colspan=1>Storage</td><td rowspan=1 colspan=4>≤-2°C</td><td rowspan=1 colspan=3>$2 -8oC$</td></tr><tr><td rowspan=1 colspan=1></td><td></td><td></td><td></td><td></td><td rowspan=1 colspan=3></td></tr><tr><td rowspan=1 colspan=1>Assay Factors</td><td rowspan=1 colspan=4>Fibrinogen</td><td rowspan=1 colspan=3>Fibrinogen</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=4></td><td rowspan=1 colspan=3></td></tr></table>

# Conclusions

Wortham Laboratories Low Fibrinogen Control and Pacific Hemostasis Low Fibrinogen Control have the same e ntiaveme i v  plaso pr citrated human plasma, obtained from normal donors with added stabilizers and buffers.

Mechanical assays produced a standard deviationf .9 or Wortham Laboratoris Fibrinogen Control, copar to a 0.095 standard deviation for Pacific Hemostasis Fibrinogen Control.

Reproducibility of the two controls yielded a $0 . 6 0 \%$ within-run coefficient of variation and a run-run $0 . 5 8 \%$ CV for Wortham Laboratories Fibrinogen Control compared respectively to the predicate control of $0 . 6 3 \%$ CV and $0 . 6 7 \%$ CV.

The pe at pentre a w shentigihabltenen ogia support the substantial equivalence claim or Wortham Laboratories Low Fibrinogen Control to Paciic Hemostasis Lo FoBs ea rovi  rlu hat he opdtsy equivalent.

# Wortham Laboratories, Inc.

# Premarket Notification 510 (k) Summary

# Fibrinogen Control Plasma

The assigned 510K number is: K060968

# Applicant:

Wortham Laboratories, Inc. 6340 Bonny Oaks Dr Chattanooga, TN 37416 Tel: (423) 296-0090 Fax: (423) 296-0188

# Contact:

Leon Wortham

# Date:

April 6, 2007

# Device Name:

Wortham Laboratories Fibrinogen Control Plasma (Normal)

# Common Name:

Fibrinogen Control Plasma

Classification Name:

Plasma, Coagulation Control, is a class II device as per 21 CFR 864.5425 (Product Code GHH). This device is intended for clinical use in conjunction with an analyzer to measure clot formation.

# Predicate:

Pacific Hemostasis Fibrinogen Assay (K800826)

# Description

Wortham Laboratories Fibrinogen Normal Control is  liquid stable preparation citrated plasma btain from hh abz ulu control has been tested by an FDA approvedmethod and found non-reactiv for HBsAg and negative or antiodies to HIV and HCV.

# Intended Use

Wor Lreon Noral ivonol plaa t  he y control of fibrinogen assays.

# Labeling

This device is labeled in accordance with 21 CFR 801.

# Substantial Equivalence

<table><tr><td rowspan=1 colspan=1>CharacteristicsIntended Use</td><td rowspan=1 colspan=4>New DeviceTo determine quantitative level of fibrinogen inplasma sample, and for quality control inmonitoring heparin therapy with APTT testing</td><td rowspan=1 colspan=3>PredicateTo determine quantitative level of fibrinogenin plasma sample, and for quality control inmonitoring heparin therapy with APTTtesting</td></tr><tr><td rowspan=1 colspan=1></td><td></td><td></td><td></td><td></td><td rowspan=1 colspan=3></td></tr><tr><td rowspan=1 colspan=1>ControlComposition</td><td rowspan=1 colspan=4>Liquid Human citrated plasma</td><td rowspan=1 colspan=3>Lypholyzed Human citrated plasma</td></tr><tr><td rowspan=1 colspan=1></td><td></td><td></td><td></td><td></td><td rowspan=1 colspan=3></td></tr><tr><td rowspan=1 colspan=1>Stability</td><td rowspan=1 colspan=4>12 months @ ≤ -2° C30 days @ 2-4° C</td><td rowspan=1 colspan=3>24 months @ 2-8° C, lypholyzed16 hours @ 2-8° C, rehydrated</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=4></td><td rowspan=1 colspan=3></td></tr><tr><td rowspan=1 colspan=1>ReferenceValues</td><td rowspan=1 colspan=3>within-run</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=2>within-run</td><td rowspan=1 colspan=1>CV%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Normal</td><td rowspan=1 colspan=1>0.56%</td><td rowspan=1 colspan=2>Normal</td><td rowspan=1 colspan=1>0.59%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Low</td><td rowspan=1 colspan=1>0.60%</td><td rowspan=1 colspan=2>Low</td><td rowspan=1 colspan=1>0.63%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>run-run</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=2>run-run</td><td rowspan=1 colspan=1>CV%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Normal</td><td rowspan=1 colspan=1>0.57%</td><td rowspan=1 colspan=2>Normal</td><td rowspan=1 colspan=1>0.60%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Low</td><td rowspan=1 colspan=1>0.58%</td><td rowspan=1 colspan=2>Low</td><td rowspan=1 colspan=1>0.67%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Expected Range</td><td rowspan=1 colspan=1>Mechanical</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=2>± 2SD</td><td rowspan=1 colspan=1>Mechanical</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>±2SD</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Normal</td><td rowspan=1 colspan=1>306.3</td><td rowspan=1 colspan=2>301-313 g/dl</td><td rowspan=1 colspan=1>Normal</td><td rowspan=1 colspan=1>306.3</td><td rowspan=1 colspan=1>297-315 g/dl</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Low</td><td rowspan=1 colspan=1>99.1</td><td rowspan=1 colspan=2>97-103 g/dl</td><td rowspan=1 colspan=1>Low</td><td rowspan=1 colspan=1>99.8</td><td rowspan=1 colspan=1>97-104 g/dl</td></tr><tr><td rowspan=1 colspan=1></td><td></td><td></td><td></td><td></td><td rowspan=1 colspan=3></td></tr><tr><td rowspan=1 colspan=1>Storage</td><td rowspan=1 colspan=4>≤-2oC</td><td rowspan=1 colspan=3>2-8°C</td></tr><tr><td rowspan=1 colspan=1></td><td></td><td></td><td></td><td></td><td rowspan=1 colspan=3></td></tr><tr><td rowspan=1 colspan=1>Assay Factors</td><td rowspan=1 colspan=4>Fibrinogen</td><td rowspan=1 colspan=3>Fibrinogen</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=4></td><td rowspan=1 colspan=3></td></tr></table>

# Conclusions

Wortham Laboratories Normal Fibrinogen Control and Pacific Hemostasis Normal Fibrinogen Control have the enu qutveunr vn lao e ep of citrated human plasma, obtained from normal donors with added stabilizers and buffers.

Mechanical assays produced a standard deviationf 0.085for Wortham LaboratoriesFirinogen Control, compared to a O.089 standard deviation for Pacific Hcmostasis Fibrinogen Control.

Reproducibility of the two controls yielded a $0 . 5 6 \%$ within-run coefficient of variation and a run-run $0 . 5 3 \%$ CV for Wortham Laboratorics Fibrinogen Control compared respectively to the predicate control of $0 . 5 9 \%$ CV and $0 . 6 0 \%$ CV.

The pean atprntre s  snisinguishabltendeusn eologila support the substantial equivalence claim for Wortham Laboratorics Normal Fibrinogen Control to Pacific H ora F nas at pro  sn hat he substantially equivalent.

# Wortham Laboratories, Inc.

# Premarket Notification 510 (k) Summary

Thrombin Reagent

The assigned 5 10K number is: K060968

# Applicant:

Wortham Laboratorics, Inc. 6340 Bonny Oaks Dr Chattanooga, TN 37416 Tel: (423) 296-0090 Fax: (423) 296-0188

# Contact:

Leon Wortham

# Date:

April 6, 2007

# Device Name:

Wortham Laboratories Thrombin Reagent

# Common Name:

Thrombin Time Test

Classification Name:

Fibrinogen Determination System, class II, 21 CFR 864.7340 (Product Code GJA and KQJ). This device is intended for clinical use in conjunction with an analyzer to measure clot formation.

# Predicate:

Pacific Hemostasis Thrombin Reagent (K970645)

# Description

Wortham Laboratories Thrombin Reagent is a liquid stable preparation f activated bovine prothrombin protcins (Factor Ha).

# Intended Use

Wortham Laboratories Thrombin Reagent is intended for thrombin to convert fibrinogen in the quantitative determination of fibrinogen in plasma samples.

# Labeling

This device is labeled in accordance with 21 CFR 801.

# Substantial Equivalence

<table><tr><td rowspan=1 colspan=1>CharacteristicsIntended Use</td><td rowspan=1 colspan=4>New DeviceTo determine quantitative level offibrinogen in plasma sample.</td><td rowspan=1 colspan=3>PredicateTo determine quantitative level offibrinogen in plasma sample.</td></tr><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=4>Y</td><td rowspan=1 colspan=3>EY</td></tr><tr><td rowspan=1 colspan=1>ReagentComposition</td><td rowspan=1 colspan=4>Liquid bovine thrombin</td><td rowspan=1 colspan=3>Lypholyzed bovine thrombin</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=4></td><td rowspan=1 colspan=3></td></tr><tr><td rowspan=1 colspan=1>Stability</td><td rowspan=1 colspan=4>12 months @≤ -2°C30 days @ 2-4° C</td><td rowspan=1 colspan=3>28 months @ 2-8° C, lypholyzed1 day @ 2-8° C, rehydrated</td></tr><tr><td rowspan=1 colspan=1>canmantaYellow</td><td rowspan=1 colspan=4>anmaentnYellowb</td><td rowspan=1 colspan=3></td></tr><tr><td rowspan=1 colspan=1>Reference Values</td><td rowspan=1 colspan=3></td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=1>CV%</td></tr><tr><td rowspan=1 colspan=1>cYanmaGentaellowb</td><td rowspan=1 colspan=3>within-run</td><td rowspan=1 colspan=1>0.67%</td><td rowspan=1 colspan=2>within-run</td><td rowspan=1 colspan=1>0.68%</td></tr><tr><td rowspan=1 colspan=1>cYanmaGentlowb</td><td rowspan=1 colspan=3>run-run</td><td rowspan=1 colspan=1>0.68%</td><td rowspan=1 colspan=2>run-run</td><td rowspan=1 colspan=1>0.71%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=4></td><td rowspan=1 colspan=3></td></tr><tr><td rowspan=1 colspan=1>Expeeted Range</td><td rowspan=1 colspan=1>Mechanical</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=2>± 2SD</td><td rowspan=1 colspan=1>Mechanical</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>± 2SD</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>119</td><td rowspan=1 colspan=2>118-120 IU/ml</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>119</td><td rowspan=1 colspan=1>118-120 1U/ml</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=4></td><td rowspan=1 colspan=3></td></tr><tr><td rowspan=1 colspan=1>Storage</td><td rowspan=1 colspan=4>≤-2o$</td><td rowspan=1 colspan=3>2-8°C</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=4></td><td rowspan=1 colspan=3>EY</td></tr><tr><td rowspan=1 colspan=1>Assay Factors</td><td rowspan=1 colspan=4>Fibrinogen</td><td rowspan=1 colspan=3>Fibrinogen</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=4></td><td rowspan=1 colspan=3></td></tr></table>

# Conclusion

Wortham Laboratorics Thrombin Reagent and Pacific Hemostasis Thrombin Reagent have the same intended use, as noral reagents or reactiv coagulation assays.Both are preparations activated bovie prothrombin po r ITh eoa pehere  w as stigihab tenue n t characteristics, support the substantial equivalence caim or Wortham Laboratories Thrombin Reagent to aciic Hemostasis Thrombin Reagent.Basedon the data provided, it is our conclusion that these two products are substantially equivalent.

# Wortham Laboratories, Inc.

# Premarket Notification 510 (k) Summary

Heparin Control Plasma

The assigned 510K number is: K060968

# Applicant:

Wortham Laboratories, Inc. 6340 Bonny Oaks Dr Chattanooga, TN 37416 Tel: (423) 296-0090 Fax: (423) 296-0188

# Contact:

Leon Wortham

# Date:

April 6, 2007

# Device Name:

Wortham Laboratories Heparin Control Plasma Level 1 $( 0 . 2 5 \mathrm { U } / \mathrm { m l } )$ EPY

# Common Name:

Heparin Control Plasma Level

Classification Name:

Plasma, Coagulation Control, is a class II device as per 21 CFR 864.5425 (Product Code GGN). This device is intended for clinical use in conjunction with an analyzer to measure clot formation.

# Predicate:

Pacific Hemostasis Heparin Control Level I (K992278)

# Description

Wortham Laboratories Heparin Control Level 1 is a liquid stable preparation of citrated plasma obtained from l  c  iz  usl preparation of the control has been tested by an FDA approved method and found non-reactive for HBsAg and negative for antibodies to HIV and HCV.

# Intended Use

Wortham Laboratories Heparin Control Level 1, is intended as a quality control of the Activated Partial Thromboplastin Time (APTT) during heparin monitoring.

# Labeling

This device is labeled in accordance with 21 CFR 801.

# Substantial Equivalence

<table><tr><td rowspan=1 colspan=1>CharacteristicsIntended Use</td><td rowspan=1 colspan=4>New DeviceUsed in heparin assay for quality control inmonitoring heparin therapy with APTT testing,yiclding slightly abnormal range for Level 1(0.25 U/ml) and marked abnorinal range forLevel 2 (0.35 U/ml)</td><td rowspan=1 colspan=3>PredicateUsed in heparin assay for quality control inmonitoring heparin therapy with APTTtesting, yielding slightly abnormal range forLevel 1 (0.25 U/ml) and marked abnormalrange for Level 2 (0.35 U/ml)</td></tr><tr><td rowspan=1 colspan=1></td><td></td><td></td><td></td><td></td><td rowspan=1 colspan=3></td></tr><tr><td rowspan=1 colspan=1>ControlComposition</td><td rowspan=1 colspan=4>Liquid Human citrated plasma with heparin</td><td rowspan=1 colspan=3>Lypholyzed Human citrated plasma withhcparin</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=4></td><td rowspan=1 colspan=3></td></tr><tr><td rowspan=1 colspan=1>Stability</td><td rowspan=1 colspan=4>12 months @ ≤ -2°C30 days @ 2-4° C</td><td rowspan=1 colspan=3>36 months @ 2-8° C, lypholyzed8 hours @ 2-8° C, rehydrated</td></tr><tr><td rowspan=1 colspan=1></td><td></td><td></td><td></td><td></td><td rowspan=1 colspan=3></td></tr><tr><td rowspan=1 colspan=1>ReferenceValues</td><td rowspan=1 colspan=3>within-run</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=2>within-run</td><td rowspan=1 colspan=1>CV%</td></tr><tr><td rowspan=1 colspan=1>cYanmaGentalowb</td><td rowspan=1 colspan=3>0.25 U/ml</td><td rowspan=1 colspan=1>1.82%</td><td rowspan=1 colspan=2>0.25 U/ml</td><td rowspan=1 colspan=1>2.14%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>0.35 U/ml</td><td rowspan=1 colspan=1>1.77%</td><td rowspan=1 colspan=2>0.35 U/ml</td><td rowspan=1 colspan=1>2.04%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>run-run</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=2>run-run</td><td rowspan=1 colspan=1>CV%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>0.25 U/ml</td><td rowspan=1 colspan=1>1.92%</td><td rowspan=1 colspan=2>0.25 U/ml</td><td rowspan=1 colspan=1>2.27%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>0.35 U/ml</td><td rowspan=1 colspan=1>1.81%</td><td rowspan=1 colspan=2>0.35 U/ml</td><td rowspan=1 colspan=1>2.07%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Expected Range</td><td rowspan=1 colspan=1>Mechanical</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=2>± 2SD</td><td rowspan=1 colspan=1>Mechanical</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>± 2SD</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Level 1</td><td rowspan=1 colspan=1>46.82</td><td rowspan=1 colspan=2>45.2-48.5 sec</td><td rowspan=1 colspan=1>Level 1</td><td rowspan=1 colspan=1>46.94</td><td rowspan=1 colspan=1>44.8-49.1 sec</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Level 2</td><td rowspan=1 colspan=1>63.49</td><td rowspan=1 colspan=2>62.4-64.6 sec</td><td rowspan=1 colspan=1>Level 2</td><td rowspan=1 colspan=1>62.64</td><td rowspan=1 colspan=1>60.1-65.2 sec</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=4></td><td rowspan=1 colspan=3></td></tr><tr><td rowspan=1 colspan=1>Storage</td><td rowspan=1 colspan=4>≤-2oC</td><td rowspan=2 colspan=3>2 -8 C</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=4></td></tr><tr><td rowspan=1 colspan=1>Assay Factors</td><td rowspan=1 colspan=4>Heparin</td><td rowspan=1 colspan=3>Heparin</td></tr><tr><td rowspan=1 colspan=1></td><td></td><td></td><td></td><td></td><td rowspan=1 colspan=3></td></tr></table>

# Conclusions

Wortham Laboratories Heparin Control Level 1 and Pacific Hemostasis Heparin Control Level  have the same intended usc, as or quality control in monioring heparn herapy with AT testg.Both are prepare from e  asT i  nve 1 Heparin Control.

Mecanical assays prouc a withn-ru sanrd dviatin0.296an a 0.930 un-standar devia Wortham Laboratories Level 1 Heparin Control, compared to the predicate control of 1.0640 and 1.0859 standard deviation, respectively.

Reproducibility of the two controls yielded a $1 . 3 3 \%$ within-run coefficient of variation and a run-run $1 . 9 2 \%$ CV for Wortham Laboratories Heparin Control Level 1, compared respectively to the predicate control of $2 . 1 5 \%$ CV and $2 . 2 7 \%$ CV.

The peat ehee  we s eisgushabtenun ololar support the substantial equivalence claim or Wortham Laboratories Hepari Control Level  to Paciic Hemostasis HCoLBas ovi  hathe py equivalent.

$$
\cos \theta \cos \theta \cos \theta
$$

# Wortham Laboratories, Inc.

# Premarket Notification 510 (k) Summary

Heparin Control Plasma

The assigned 510K number is: K060968

# Applicant:

Wortham Laboratories, Inc. 6340 Bonny Oaks Dr Chattanooga, TN 37416 Tel: (423) 296-0090 Fax: (423) 296-0188

# Contact:

Leon Wortham

# Date:

April 6, 2007

# Device Name:

Wortham Laboratorics Heparin Control Plasma Level 2 $( 0 . 3 5 ~ \mathrm { U / m l } )$ ..

# Common Name:

Heparin Control Plasma Level 2

Classification Name:

Plasma, Coagulation Control, is a class II device as per 21 CFR 864.5425 (Product Code GGN). This device is intended for clinical use in conjunction with an analyzer to measure clot formation.

# Predicate:

Pacific Hemostasis Heparin Control Level II (K992279)

# Description

Wortham Laboratories Heparin Control Level  is a liquid stable preparation of citrated plasma obtained from o  c  iz  u u preparation of the control has been tested by an FDA approved method and found non-reactive for HBsAg and negative for antibodics to HIV and HCV.

# Intended Use

Wortham Laboratories Heparin Control Levcl 2, is intended as a quality control of the Activated Partial Thromboplastin Time (APTT) during heparin monitoring.

# Labeling

This device is labeled in accordance with 21 CFR 801.

# Substantial Equivalence

<table><tr><td rowspan=1 colspan=1>CharacteristicsIntended Use</td><td rowspan=1 colspan=4>New DeviceUsed in heparin assay for quality control inmonitoring heparin therapy with APTT testing,yielding slightly abnormal range for Level 1(0.25 U/ml) and marked abnormal range forLevel 2 (0.35 U/ml)</td><td rowspan=1 colspan=3>PredicateUsed in heparin assay for quality control inmonitoring heparin therapy with APTTtesting, yielding slightly abnormal range forLevel 1 (0.25 U/ml) and marked abnormalrange for Level 2 (0.35 U/ml)</td></tr><tr><td rowspan=1 colspan=1></td><td></td><td></td><td></td><td></td><td rowspan=1 colspan=3></td></tr><tr><td rowspan=1 colspan=1>ControlComposition</td><td rowspan=1 colspan=4>Liquid Human citrated plasma with heparin</td><td rowspan=1 colspan=3>Lypholyzed Human citrated plasma withheparin</td></tr><tr><td rowspan=1 colspan=1></td><td></td><td></td><td></td><td></td><td rowspan=1 colspan=3></td></tr><tr><td rowspan=1 colspan=1>Stability</td><td rowspan=1 colspan=4>12 months @ ≤ -2°C30 days @ 2-4°C</td><td rowspan=1 colspan=3>36 months @ 2-8° C, lypholyzed8 hours @ 2-8° C, rehydrated</td></tr><tr><td rowspan=1 colspan=1>canmantelow</td><td></td><td></td><td></td><td></td><td rowspan=1 colspan=3></td></tr><tr><td rowspan=1 colspan=1>ReferenceValues</td><td rowspan=1 colspan=3>within-run</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=2>within-run</td><td rowspan=1 colspan=1>CV%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>0.25 U/ml</td><td rowspan=1 colspan=1>1.82%</td><td rowspan=1 colspan=2>0.25 U/ml</td><td rowspan=1 colspan=1>2.14%</td></tr><tr><td rowspan=1 colspan=1>cYanmaGentaYlowb</td><td rowspan=1 colspan=3>0.35 U/ml</td><td rowspan=1 colspan=1>1.77%</td><td rowspan=1 colspan=2>0.35 U/ml</td><td rowspan=1 colspan=1>2.04%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>run-run</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=2>run-run</td><td rowspan=1 colspan=1>CV%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>0.25 U/ml</td><td rowspan=1 colspan=1>1.92%</td><td rowspan=1 colspan=2>0.25 U/ml</td><td rowspan=1 colspan=1>2.27%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>0.35 U/ml</td><td rowspan=1 colspan=1>1.81%</td><td rowspan=1 colspan=2>0.35 U/ml</td><td rowspan=1 colspan=1>2.07%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Expected Range</td><td rowspan=1 colspan=1>Mechanical</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=2>± 2SD</td><td rowspan=1 colspan=1>Mechanical</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>± 2SD</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Level 1</td><td rowspan=1 colspan=1>46.82</td><td rowspan=1 colspan=2>45.2-48.5 sec</td><td rowspan=1 colspan=1>Level 1</td><td rowspan=1 colspan=1>46.94</td><td rowspan=1 colspan=1>44.8-49.1 sec</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Level 2</td><td rowspan=1 colspan=1>63.49</td><td rowspan=1 colspan=2>62.4-64.6 sec</td><td rowspan=1 colspan=1>Level 2</td><td rowspan=1 colspan=1>62.64</td><td rowspan=1 colspan=1>60.1-65.2 sec</td></tr><tr><td rowspan=1 colspan=1></td><td></td><td></td><td></td><td></td><td rowspan=1 colspan=3></td></tr><tr><td rowspan=1 colspan=1>Storage</td><td rowspan=1 colspan=4>≤-2°</td><td rowspan=2 colspan=3>2 -8o$</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=4></td></tr><tr><td rowspan=1 colspan=1>Assay Factors</td><td rowspan=1 colspan=4>Heparin</td><td rowspan=1 colspan=3>Heparin</td></tr><tr><td rowspan=1 colspan=1></td><td></td><td></td><td></td><td></td><td rowspan=1 colspan=3></td></tr></table>

# Conclusions

Wortham Laboratories Heparin Control Level 2 and Pacific Hemostasis Heparin Control Level 2 have the samc inted use, as or qualiy control in monioring hepar therapy with APTT testg.Both are prepar from r  asTel il     v 2 Heparin Control.

Mcnil assas prouce a within-u anard dvatn1.120an a1.16 u-ustanar eviai Wortham Laboratories Level 2 Heparin Control, compared to the predicate control of 1.2775 and 1.2975 standard deviation, respectively.

Reproducibility of the two controls yiclded a $1 . 7 7 \%$ within-run cocfficicnt of variation and a run-run $1 . 8 1 \%$ CV for Wortham Laboratories Heparin Control Level 2, compared respectively to the predicate control of $2 . 0 4 7 \%$ CV and $2 . 0 7 \%$ CV.

The perran dta prenthere as we as thenistnguishabteneuse nd teologiclchrc support the substantal equivalence claim or Wortham Laboratoris Hepar Control Level  to Paciic Hemostasis

$$
1 / \sin \theta \theta \theta \theta \theta \theta
$$

# WORTHAM LABORATORIES, INC.

DRAFT   
Calcium Chloride   
0.02 M

# Intended Use

Wortham Laboratories Calcium Chloride Solution $0 . 0 2 \mathrm { ~ M ~ } ( \mathrm { C a C } ; \mathrm { l } _ { 2 } )$ is intended for quantitative use with ellaicacid (Intrin-EA) or silicon particulate activators (Intrin-Sl) in performing the activated partial thromboplastin time (APTT) on citrated plasma.

Refer to Catalogue Number 4002-03-1 ((ntrin-S1) Refer to Catalogue Number 4002-03-2 (Intrin-EA)

# Reagents

IVD For in vitro diagnostic use

Composition: $0 . 2 2 2 \%$ M calcium chloride, $0 . 1 \%$ sodium azide.

Warning: Calcium Chloride Solution contains sodium azide. Sodium azide under acid conditions yields hydrozoic acid, an extremely toxic compound. Dilute with running water before discarding, and then flush with a large volume of water.These precautions are recommended to avoid deposits in metal pipetting in which explosive conditions may develop.

Store this product at $\leq - 2 ^ { \circ } \mathrm { C }$ .

# Materials Provided:

Calcium Chloride (0.02M), 1 x 10 ml

Ordering Information

Cat. No. Description Contents 4002-04-1 CaCl2 (0.02M) 10 ml 4002-03-1 Intrin-SI 10ml 4002-03-2 Intrin-EA 10ml

# Wortham Laboratories, Inc.

Premarket Notification 510 (k) Summary

Fibrinogen Assay Set

The assigned 510K number is: K060968

# Applicant:

Wortham Laboratories, Inc. 6340 Bonny Oaks Dr Chattanooga, TN 37416 Tel: (423) 296-0090 Fax: (423) 296-0188

# Contact:

Lcon Wortham

# Date:

April 6, 2007

# Device Name:

Wortham Laboratories Fibrinogen Assay Set

Common Name:

Fibrinogen Control Plasma

Classification Name:

Plasma, Coagulation Control, is a class II device as per 21 CFR 864.5425 (Product Code GHH). This device is intended for clinical use in conjunction with an analyzer to measure clot formation.

# Predicate:

Pacific Hemostasis Fibrinogen Assay (K800826)

# Description

Wortham Laboratories Fibrinogen Assay Set contains a liquid stable preparation  citrate plasmabtaine m u c unl use e hol s bes A method and found non-reactive for HBsAg and negative for antibodies to HIV and HCV.

# Intended Use

Wortham Laboratories Fibrinogen Assay Set, containing a complete set of Normal Fibrinogen Control (200-400 mg/dl), Thrombin Reagent $( 1 0 0 \mathrm { I U / m l } )$ of fibrinogen in plasma samples.

# Labeling

This device is labeled in accordance with 21 CFR 801.

# Substantial Equivalence

<table><tr><td rowspan=1 colspan=1>CharacteristicsIntended Use</td><td rowspan=1 colspan=4>New DeviceTo determine quantitative level of fibrinogen inplasma sample, and for quality control inmonitoring heparin therapy with APTT testing</td><td rowspan=1 colspan=3>PredicateTo determine quantitative level of fibrinogenin plasma sample, and for quality control inmonitoring heparin therapy with APTTtesting</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=4></td><td rowspan=1 colspan=3></td></tr><tr><td rowspan=1 colspan=1>ReagentComposition</td><td rowspan=1 colspan=4>Liquid Bovine Thrombin</td><td rowspan=1 colspan=3>Lypholyzed Bovine Thrombin</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=4></td><td rowspan=1 colspan=3></td></tr><tr><td rowspan=1 colspan=1>Stability</td><td rowspan=1 colspan=4>12 months @ ≤ -2°C30 days @ 2-4° C</td><td rowspan=1 colspan=3>24 months @ 2-8° C, lypholyzed16 hours @ 2-8° C, rehydrated</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=4></td><td rowspan=1 colspan=3></td></tr><tr><td rowspan=1 colspan=1>ReferenceValues</td><td rowspan=1 colspan=3>within-run</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=2>within-run</td><td rowspan=1 colspan=1>CV%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Normal</td><td rowspan=1 colspan=1>0.56%</td><td rowspan=1 colspan=2>Normal</td><td rowspan=1 colspan=1>0.59%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Low</td><td rowspan=1 colspan=1>0.60%</td><td rowspan=1 colspan=2>Low</td><td rowspan=1 colspan=1>0.63%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>run-run</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=2>run-run</td><td rowspan=1 colspan=1>CV%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Normal</td><td rowspan=1 colspan=1>0.57%</td><td rowspan=1 colspan=2>Normal</td><td rowspan=1 colspan=1>0.60%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Low</td><td rowspan=1 colspan=1>0.58%</td><td rowspan=1 colspan=2>Low</td><td rowspan=1 colspan=1>0.67%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Expected Range</td><td rowspan=1 colspan=1>Mechanical</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=2>±2SD</td><td rowspan=1 colspan=1>Mechanical</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>± 2SD</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Normal</td><td rowspan=1 colspan=1>306.3</td><td rowspan=1 colspan=2>301-313 g/dl</td><td rowspan=1 colspan=1>Normal</td><td rowspan=1 colspan=1>306.3</td><td rowspan=1 colspan=1>297-315 g/dl</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Low</td><td rowspan=1 colspan=1>99.1</td><td rowspan=1 colspan=2>97-103 g/dl</td><td rowspan=1 colspan=1>Low</td><td rowspan=1 colspan=1>99.8</td><td rowspan=1 colspan=1>97-104 g/d1</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=4></td><td rowspan=1 colspan=3></td></tr><tr><td rowspan=1 colspan=1>Storage</td><td rowspan=1 colspan=4>≤-2°C</td><td rowspan=1 colspan=3>2-8oC$</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=4></td><td rowspan=1 colspan=3></td></tr><tr><td rowspan=1 colspan=1>Assay Factors</td><td rowspan=1 colspan=4>Fibrinogen</td><td rowspan=1 colspan=3>Fibrinogen</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=4></td><td rowspan=1 colspan=3></td></tr></table>

# Conclusions

Wortham Laboratories Fibrinogen Assay Set and Pacific Hemostasis Fibrinogen Assay Set have the same intended u pa humn plasma aie o ormal onors wih ade ablizrs nd buffrandus bovi  he activating reagent.

Mcl ar .W   o to a 0.089 standard deviation for Pacific Hemostasis Fibrinogen Control.

Reproducibility of the two controls yielded a $0 . 5 6 \%$ within-run coefficient of variation and a run-run $0 . 5 3 \%$ CV for Wortham Laboratories Fibrinogen Control compared respectively to the predicate control of $0 . 5 9 \%$ CV and $0 . 6 0 \%$ CV.

T  h support the substantial equivalence claim or Wortham Laboratories Fibrinogen Assay Set to Paciic Hemostasis ySBashe a poi  scusn h he equivalent.

$$
\{ \zeta \cup \zeta \} . \zeta \cup \}
$$

# DRAFT Fibrinogen Buffer

# Intended Use

Buffer is designed as a diluent for fibrinogen studies.

# Reagents

IVD For in vitro diagnostic use

Fibrinogen Buffer : $1 . 3 \%$ TAPSO Buffer. $0 . 9 \%$ sodium chloride. $0 . 1 \%$ sodium azide and stabilizers; pH $7 . 3 5 \pm 0 . 0 5$ .

Store at $\leq - 2 ^ { \circ } \mathrm { C }$ .Unused portions of open bottles will remain stable when stored at $2 { - } 4 ^ { \circ } C$ unless contaminated.

Avoid contamination by exercising care during multiple pipettings. Physical signs of deterioration are limited to visual microbial contamination.

Warning: Fibrinogen Buffer contains sodium azide. Sodium azide under acidic conditions yields hydrozoic acid, and extremely toxic compound. Azide compounds should be flushed with large volumes of water. Those prccautions are recommended to avoid deposits in metal pipes in which explosive conditions may develop.

# Ordering Information

<table><tr><td>Cat No.</td><td>Description</td><td>Contents</td></tr><tr><td>4002-05-3</td><td>Fibrinogen Buffer</td><td>100ml</td></tr><tr><td>4002-05-1</td><td>Fibrinogen Control, Normal</td><td>10 ml</td></tr><tr><td>4002-05-2</td><td>Fibrinogen Control, Low</td><td>1(0ml</td></tr><tr><td>4002-05-3</td><td>Fibrinogen Assay Set</td><td></td></tr><tr><td></td><td>Fibrinogen Control Normal</td><td>5 ml</td></tr><tr><td></td><td>Thrombin Reagent</td><td>5 ml</td></tr><tr><td></td><td>Fibrinogen Buffer</td><td>200 ml</td></tr></table>

# MAY 1 5 2007

Mr. Leon Wortham, President and CEO Wortham Laboratories, Inc. 6340 Bonny Oaks Drive Chattanooga, TX 37416

Re: k060968 Trade/Device Name: Wortham Laboratories Stasis 1 Coagulation Control (Normal) Regulation Number: 21 CFR 864.5425 Regulation Name: Multipurpose System for in vitro coagulation studies. Regulatory Class: Class II Product Code: GIZ, GGC, GGN, GJS, GFO, GIL, KQJ Dated: April 05, 2007 Received: April 09, 2007

Dear Mr. Wortham:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devicshat havebeen eclassifi i accordance with the provisions  the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class I (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with al the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page 2 -

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0484. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address   
http://www.fda.gov/cdrh/industry/support/index.html

Sincerely yours,

fobath Beckerh

Robert L. Becker, Jr., MD, PH.D   
Director   
Division of Immunology and Hematology   
Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Center for Devices and   
Radiological Health

# Indications for Use

510(k) Number (if known): K060968

Device Name: Wortham Laboratories Stasis 1 Coagulation Control (Normal)

Indications For Use:

Wortham Laboratories Stasis 1 Coagulation Control (Normal) is intended for use as a quality control to monitor the performance of Prothrombin Time (PT), Activated Partial Thromboplastin Time (APTT) and Fibrinogen assays. It wil yield PT, APTT, and Fibrinogen values in the normal range.

Concurrence of CDRH, Offce of Device Evaluation (ODE)

Brutid   
Division Sigoff   
Office of In Vitro Diagnostic Device   
Evaluation and Safety   
510(k) K060968

Page l of

# Indications for Use

510(k) Number (if known): K060968

Device Name: Wortham Laboratories Stasis 2 Coagulation Control (Abnormal)

Indications For Use:

Wortham Laboratories Stasis 2 Coagulation Control (Abnormal) is intended for use as a quality control to monitor the performance of Prothrombin Time (PT), Activated Partial Thromboplastin Time (APTT). It will yield PT, and APTT values in the moderate abnormal range.

Concurrence of CDRH, Office of Device Evaluation (ODE)

11 chime Cuteli Divisigy Signfoff

Office of In Vitro Diagnostic Device Evaluation and Safety

Page 1 of

310(k). K060968

# Indications for Use

510(k) Number (if known): K060968

Device Name: Wortham Laboratories Stasis 3 Coagulation Control (Abnormal)

Indications For Use:

Wortham Laboratories Stasis 3 Coagulation Control (Abnormal) is intended for use as a quality control to monitor the performance of Prothrombin Time (PT), Activated Partial Thromboplastin Time (APTT). It will yield PT, and APTT values in the strongly abnormal range.

Concurrence of CDRH, Office of Device Evaluation (ODE)

Auphin   
Divisign Sigh-off   
Office of In Vitro Diagnostic Device   
Evaluation and Safety   
10(k) K060968

Page 1 of

# Indications for Use

510(k) Number (if known): K060968

Device Name: Wortham Laboratories Serathan-B PT Reagent

Indications For Use:

Wortham Laboratorics Serathan-B PT reagent is an in-vitro diagnostic reagent intended in a clinical laboratory for the quantitative determination of Prothrombin Time (PT) testing for the detection of coagulation abnormalities in the extrinsic pathway. Serathan-B is a moderately sensitive thromboplastin reagent.

Concurrence of CDRH, Office of Device Evaluation (ODE) Suphini Brutidi ivigigh Sigff Office of In Vitro Diagnostic Device Evaluation and Safety 10K060968

Page l of

# Indications for Use

510(k) Number (ifknown): K060968

Device Name: Wortham Laboratories Serathan-A PT Reagent

Indications For Use:

Wortham Laboratories Serathan-A PT reagent is an in-vitro diagnostic reagent intended in a clinical laboratory for the quantitative determination of Prothrombin Time (PT) testing for the detection of coagulation abnormalities in the extrinsic pathway. Serathan-A is a highly sensitive thromboplastin reagent.

visiy Ssigfoft Jughin Brati Concurrence of CDRH Office of Device Evaluation (ODE)   
Office of In Vitro Diagnostic Device   
Evaluation and Safety   
0(k) K060968

Page 1 of

# Indications for Use

510(k) Number (if known): K060968

Device Name: Wortham Laboratories Intrin-EA APTT Reagent

Indications For Use:

Wortham Laboratories Intrin-EA APTT is an in-vitro diagnostic reagent used in the clinical laboratory for the quantitative determination of Activated Partial Thromboplastin Time (APTT) etilat lit h paIn is sensitive to mild coagulopathies.

nrecRHff  Devvalan DE) Juphine Sautdi   
vision Sign Off   
Office of In Vitro Diagnostic Device   
Evaluation and Safety Page 1 of 10(0). K060968

# Indications for Use

510(k) Number (if known): K060968

Device Name: Wortham Laboratories Intrin-SI APTT Reagent

Indications For Use:

Wortham Laboratories Intrin-SI is an in-vitro diagnostic reagent used in the clinical laboratory for the quantitative determination of Activated Partial Thromboplastin Time (APTT) testing for the detection of coagulation abnormalities in the intrinsic pathway. Intrin-SI reagent is sensitive to heparin and lupus anticoagulant plasmas.

Concurrence of CDRH, Office of Device Evaluation (ODE)

ision Siof Lauthn Office of In Vitro Diagnostic Device Evaluation and Safety on k060968

Page 1 of

# Indications for Use

510(k) Number (if known): K060968

# Device Name: Wortham Laboratories Fibrinogen Control Plasma Low

Indications For Use:

Wortham Laboratories Fibrinogen Control Low, a quantitative control plasma, is intended for use in the quality control of fibrinogen assays.

Concurrence of CDRH, Office of Device Evaluation (ODE)

s Sio   
Office of In Vitro Diagnostic Device   
Evaluation and Safety 2 K060968

Page 1 of

# Indications for Use

510(k) Number (if known): K060968

# Device Name: Wortham Laboratories Fibrinogen Control Plasma Normal

Indications For Use:

Wortham Laboratories Fibrinogen Control Normal, a quantitative control plasma, is intended for use in the qualiy control o fbrinogen assys.

Concurrence of CDRH, Office of Device Evaluation (ODE) pon Sigo   
Office of In Vitro Diagnostic Device   
Evaluation and Safety K060968

Page 1 of

# Indications for Use

510(k) Number (if known): K060968

# Device Name: Wortham Laboratories Thrombin Reagent

Indications For Use:

Wortham Laboratories Thrombin Reagent is intended for thrombin to convert fibrinogen in the quantitative determination of fibrinogen in plasma samples.

Concurrence of CDRH, Offce of Device Evaluation (ODE)

ughin fien Sbuutii Office of In Vitro Diagnostic Device Evaluation and Safety K060968

Page 1 of

# Indications for Use

510(k) Number (if known): K060968

Device Name: Wortham Laboratories Fibrinogen Assay Set

Indications For Use:

Wortham Laboratories Fibrinogen Assay Set, containing a complete set of Normal Fibrinogen Control (200-400 mg/dl), Thrombin Reagent (100 IU/ml), and Fibrinogen Buffer, is intended for use in the quantitative determination of fibrinogen in plasma samples.

Concurrence of CDRH, Office of Device Evaluation (ODE)

ffice of In Vitro Diagnostic Device aluation and Safety

Page 1 of

K060968

# Indications for Use

510(k) Number (if known): K060968

Device Name: Wortham Laboratories Heparin Control Plasma Level 1

Indications For Use:

Wortham Laboratories Heparin Control Level 1, is intended as a quality control of the Activated Partial Thromboplastin Time (APTT) during heparin monitoring.

Concurrence of CDRH, Office of Device Evaluation (ODE) Sghmi Batdi

Office of In Vitro Diagnostic Device valuation and Safety

Page I of

K060968

# Indications for Use

510(k) Number (if known): K060968

Device Name: Wortham Laboratories Heparin Control Plasma Level 2

Indications For Use:

Wortham Laboratories Heparin Control Level 2, is intended as a quality control of the Activated Partial Thromboplastin Time (APTT) during heparin monitring.

Concurrence of CDRH, Office of Device Evaluation (ODE) Suphine Lotli 5igyOff   
ffice of In Vitro Diagnostic Device   
valuation and Safety K060968

Page 1 of

# Indications for Use

510(k) Number (ifknown): K060968

Device Name: Wortham Laboratories Calcium Chloride Solution $0 . 0 2 { \ : } \mathrm { M }$

Indications For Use:

Wortham Laboratories Calcium Chloride Solution $0 . 0 2 \mathrm { M } \left( \mathrm { C a C l } _ { 2 } \right)$ is intended for quantitative el (-A  puaivat nt-Si pe activated partial thromboplastin time (APTT) on citrated plasma.

Concurrence of CDRH, Office of Device Evaluation (ODE)

![](images/daa3c9bc5c6e5d6ed6d187ca0bef5e047491be2e2ae8e39be2247be974b42fc0.jpg)

Ifice of In Vitro Diagnostic Device cluation and Safety

Page l of

# Indications for Use

510(k) Number (if known): K060968

Device Name: Wortham Laboratories Fibrinogen Buffer

Indications For Use:

Wortham Laboratories Fibrinogen Buffer is designed as a diluent for fibrinogen studies.

Concurrence of CDRH, Office of Device Evaluation (ODE)

![](images/293978c67e5636164da472f65a632ac16f5295d31fd10a1e7bf9b50f0cc1eb52.jpg)

Sce of In Vitro Diagnostic Device voluation and Safety

Page 1 of